

<https://helda.helsinki.fi>

---

## High Bone Mass Disorders : New Insights From Connecting the Clinic and the Bench

Bergen, Dylan J. M.

2023-02

---

Bergen , D J M , Maurizi , A , Formosa , M M , McDonald , G L K , El-Gazzar , A , Hassan , N , Brandi , M-L , Riancho , J A , Rivadeneira , F , Ntzani , E , Duncan , E L , Gregson , C L , Kiel , D P , Zillikens , M C , Sangiorgi , L , Hogler , W , Duran , I , Mäkitie , O , Van Hul , W & Hendrickx , G 2023 , ' High Bone Mass Disorders : New Insights From Connecting the Clinic and the Bench ' , Journal of Bone and Mineral Research , vol. 38 , no. 2 , pp. 229-247 . <https://doi.org/10.1002/jbmr.4715>

---

<http://hdl.handle.net/10138/354216>

<https://doi.org/10.1002/jbmr.4715>

---

cc\_by

publishedVersion

---

*Downloaded from Helda, University of Helsinki institutional repository.*

*This is an electronic reprint of the original article.*

*This reprint may differ from the original in pagination and typographic detail.*

*Please cite the original version.*

# High Bone Mass Disorders: New Insights From Connecting the Clinic and the Bench

Dylan J.M. Bergen,<sup>1,2</sup> Antonio Maurizi,<sup>3</sup> Melissa M. Formosa,<sup>4,5</sup> Georgina L.K. McDonald,<sup>1</sup> Ahmed El-Gazzar,<sup>6</sup> Neelam Hassan,<sup>2</sup> Maria-Luisa Brandi,<sup>7</sup> José A. Riancho,<sup>8</sup> Fernando Rivadeneira,<sup>9</sup> Evangelia Ntzani,<sup>10,11,12</sup> Emma L. Duncan,<sup>13,14</sup> Celia L. Gregson,<sup>2</sup> Douglas P. Kiel,<sup>15</sup> M. Carola Zillikens,<sup>9</sup> Luca Sangiorgi,<sup>16</sup> Wolfgang Högl,<sup>6,17</sup> Ivan Duran,<sup>18</sup> Outi Mäkitie,<sup>19,20,21</sup> Wim Van Hul,<sup>22</sup> and Gretl Hendrickx<sup>23</sup>

<sup>1</sup>School of Physiology, Pharmacology, and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK

<sup>2</sup>Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK

<sup>3</sup>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

<sup>4</sup>Department of Applied Biomedical Science, Faculty of Health Sciences, University of Malta, Msida, Malta

<sup>5</sup>Center for Molecular Medicine and Biobanking, University of Malta, Msida, Malta

<sup>6</sup>Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria

<sup>7</sup>Italian Bone Disease Research Foundation (FIRMO), Florence, Italy

<sup>8</sup>Department of Internal Medicine, Hospital U M Valdecilla, University of Cantabria, IDIVAL, Santander, Spain

<sup>9</sup>Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>10</sup>Department of Hygiene and Epidemiology, Medical School, University of Ioannina, Ioannina, Greece

<sup>11</sup>Center for Evidence Synthesis in Health, Policy and Practice, Center for Research Synthesis in Health, School of Public Health, Brown University, Providence, RI, USA

<sup>12</sup>Institute of Biosciences, University Research Center of Ioannina, University of Ioannina, Ioannina, Greece

<sup>13</sup>Department of Twin Research & Genetic Epidemiology, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

<sup>14</sup>Department of Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK

<sup>15</sup>Marcus Institute for Aging Research, Hebrew SeniorLife and Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School, Broad Institute of MIT & Harvard, Cambridge, MA, USA

<sup>16</sup>Department of Rare Skeletal Diseases, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy

<sup>17</sup>Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

<sup>18</sup>University of Malaga, Malaga, Spain

<sup>19</sup>Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

<sup>20</sup>Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland

<sup>21</sup>Folkhälsan Research Centre, Folkhälsan Institute of Genetics, Helsinki, Finland

<sup>22</sup>Department of Medical Genetics, University of Antwerp, Antwerp, Belgium

<sup>23</sup>Department of Human Genetics, KU Leuven, Leuven, Belgium

## ABSTRACT

Monogenic high bone mass (HBM) disorders are characterized by an increased amount of bone in general, or at specific sites in the skeleton. Here, we describe 59 HBM disorders with 50 known disease-causing genes from the literature, and we provide an overview of the signaling pathways and mechanisms involved in the pathogenesis of these disorders. Based on this, we classify the known HBM genes into HBM (sub)groups according to uniform Gene Ontology (GO) terminology. This classification system may aid in hypothesis generation, for both wet lab experimental design and clinical genetic screening strategies. We discuss how functional genomics can

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Received in original form May 25, 2022; revised form September 5, 2022; accepted September 22, 2022.

Address correspondence to: Dylan J.M. Bergen, PhD, School of Physiology, Pharmacology, and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK; Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK. E-mail: [dylan.bergen@bristol.ac.uk](mailto:dylan.bergen@bristol.ac.uk)

Gretl Hendrickx, PhD, Laboratory for Skeletal Dysplasia Research, Department of Human Genetics, KU Leuven, Herestraat 49, Leuven 3000, Belgium. E-mail: [gretl.hendrickx@kuleuven.be](mailto:gretl.hendrickx@kuleuven.be)

Additional Supporting Information may be found in the online version of this article.

Journal of Bone and Mineral Research, Vol. 00, No. 00, Month 2022, pp 1–19.

DOI: 10.1002/jbmr.4715

© 2022 The Authors. *Journal of Bone and Mineral Research* published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

shape discovery of novel HBM genes and/or mechanisms in the future, through implementation of omics assessments in existing and future model systems. Finally, we address strategies to improve gene identification in unsolved HBM cases and highlight the importance for cross-laboratory collaborations encompassing multidisciplinary efforts to transfer knowledge generated at the bench to the clinic. © 2022 The Authors. *Journal of Bone and Mineral Research* published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

**KEY WORDS:** DISEASES AND DISORDERS OF/RELATED TO BONE; ANABOLICS; THERAPEUTICS; GENETIC ANIMAL MODELS; ANIMAL MODELS; CELL/TISSUE SIGNALING; PARACRINE PATHWAYS; GENETIC RESEARCH

## Introduction

The lifelong dynamics of bone health depend on the bone remodeling cycle, where a continuous interplay between age-related, environmental and genetic risk factors affect the metabolic activity of bone building cells (osteoblasts) and bone degrading cells (osteoclasts).<sup>(1)</sup> In a healthy setting, the metabolic equilibrium of bone anabolism and catabolism results in the preservation of a mineralized organic matrix. When this balance is disrupted, individuals are prone to develop disorders with either low bone mass (LBM) or elevated bone mass with or without dense bones, commonly known as high bone mass (HBM). LBM, the most common disorder being osteoporosis, is defined as an areal bone mineral density (aBMD) *T*-score of  $\leq -2.5$  at the post-anterior lumbar spine, hip, radius, or whole body by dual-energy X-ray absorptiometry (DXA) scans in postmenopausal women and males older than 50 years, or an aBMD *Z*-score of  $\leq -2.0$  in premenopausal women and young adults (<50 years).<sup>(2-4)</sup> Monogenic LBM disorders have been reviewed in detail in the first flagship paper published on behalf the GEMSTONE Working Group 3 COST Action.<sup>(4)</sup> In the case of HBM, a net gain of bone mass may often result from a decreased osteoclastic bone resorption, an increased osteoblastic bone formation, and/or a change in the cellular coupling between osteoblasts and osteoclasts favoring anabolism. In this review we focus on genetic disorders of primary HBM that are defined by a generalized increase in *Z*-score of at least  $+2.5$  in aBMD in at least two skeletal sites by DXA.<sup>(5)</sup>

Understanding the clinical and functional features and genetic causes of extreme phenotypes with HBM can improve diagnostics and treatment of patients. Moreover, simultaneously, novel biological drug targets may be discovered, allowing development of new therapies for osteoporosis. A prominent example of such success was the discovery of loss-of-function (LoF) mutations in *SOST* encoding sclerostin in families with sclerosteosis (OMIM 269500) and van Buchem disease (OMIM 239100), two severe HBM conditions.<sup>(6-8)</sup> A concerted multidisciplinary research effort then unraveled the precise function and effects of sclerostin in the regulation of bone mass, leading to the development of potent osteoporosis therapies; ie, anti-sclerostin antibodies (eg, romosozumab, bloszumab).<sup>(9)</sup> Over the past few decades, the listing, definition and our knowledge on rare and ultrarare HBM disorders has expanded significantly. Because HBM disorders are multifaceted, this research comprises multiple disciplines, from in-depth phenotyping and genetic screening of patients to basic wet-lab science, bringing together molecular and cell biologists, system biologists, and clinician researchers.

In this review, we discuss strategies to advance both clinical genetic knowledge and functional understanding of mechanisms leading to HBM. Similar mechanisms that predispose to secondary or artifactual forms of HBM (eg, osteoarthritis, ankylosing spondylitis, vascular calcification, incidentaloma, etc.) and ectopic bone formation in soft tissues (eg, fibrodysplasia

ostificans progressiva [FOP]) are beyond the scope of this review and have recently been reviewed elsewhere.<sup>(5,10,11)</sup> We focus on the mechanisms that underpin the development of monogenic Mendelian HBM disorders. We discuss knowledge collected from functional studies and describe how the HBM field can advance its functional understanding by scrutinizing currently lesser studied mechanisms. Finally, we classify all known HBM genes and their associated disorders according to their role in a signaling pathway or biological process, using uniform Gene Ontology (GO) accession numbers to create HBM (sub)groups.


## Knowledge of Disease Mechanisms Identified in Monogenic Disorders

Most of our knowledge concerning Mendelian, ie, monogenic, HBM disorders and mechanisms has been based on forward genetic approaches. Forward genetics begins with the identification of a HBM phenotype in the clinic, followed by determining the genetic cause of that phenotype and, mostly, functional experiments to confirm the causality of the identified variant.<sup>(3,4)</sup>

### Current gene identification strategies

Screening an individual with HBM for pathological variants in the known causative genes is, in many countries, now routine, through the clinical application of high-throughput sequencing (HTS) (reviewed elsewhere).<sup>(12)</sup> HTS technologies, previously referred to as next generation sequencing (NGS), have created a paradigm shift in genomics, offering rapid, HTS. Targeted gene panels for specific pathways or skeletal dysplasias are therefore the current gold standard and offer a powerful first-line diagnostic tool.<sup>(13)</sup> A broader approach can then be undertaken in the form of whole-exome sequencing (WES) or whole-genome sequencing (WGS) on the affected individual(s) or as a trio-sequencing approach, if DNA from parents is available (reviewed elsewhere).<sup>(4)</sup> If multiplex families are available, linkage analysis, alone or coupled with WES/WGS and co-segregation analysis, can determine the genomic region harboring the causal gene(s)—an approach that has been successfully applied in several HBM disorders.<sup>(14-16)</sup> Nevertheless, the success of genetic studies has not been without constraints, due to the lack of large multiplex families, genetic and phenotypic heterogeneity, imprinting, incomplete penetrance, epistasis, and environment interactions. Gene-burden testing overcomes some of these limitations by comparing the cumulative effects of multiple rare, protein-altering variants between cases and controls.<sup>(17)</sup> Large-scale public sequencing databases (eg, Genome Aggregation Database [gnomAD])<sup>(18)</sup> have further supported this notion by providing control sequencing data.

Despite these challenges, current gene discovery strategies have so far identified 50 genes as causal for monogenic disorders with significant HBM (Fig. 1). These genes all encode proteins that regulate signaling pathways or biological processes with



**Fig. 1.** Overview of HBM genes and their associated biological processes and pathways. Graphical overview of the currently known genes that harbor pathogenic variants causing HBM. The genes were allocated to their role in the main bone cell types (or lack of), and subsequently subdivided to a biological process and/or signaling pathway, resulting in 10 groups of HBM genes (numbered). HBM = high bone mass.

the potential to increase BMD. Undoubtedly, understanding the etiology of these disorders will inform biological function relevant to bone biology.

### Key biological processes shaped by the study of monogenic HBM disorders

#### WNT/β-catenin signaling

Genetic knowledge of HBM has shown us the importance of signaling pathways in bone development and homeostasis. A textbook example is the discovery of enhanced canonical WNT/β-catenin signaling induced by pathogenic variants in *SOST*, *LRP4*, *LRP5*, and *LRP6* in individuals with extreme HBM disorders; ie, sclerosteosis (OMIM 269500; 614305), van Buchem disease (OMIM 239100), craniodiaphyseal dysplasia (OMIM 122860), endosteal hyperostosis (OMIM 144750) and generalized osteosclerosis (OMIM n.a. [not available]) (Fig. 1).<sup>(6,8,16,19-21)</sup> These phenotypes revealed a osteoanabolic potential, as this elevated

signaling activity resulted in increased bone formation and extremely dense and fracture-resistant bones.<sup>(22)</sup> In the WNT/β-catenin pathway, cytoplasmic β-catenin is phosphorylated by the destruction complex (ie, Axin, GSK-3β, Dishevelled, etc.) which leads to proteasomal degradation, preventing β-catenin to translocate into the nucleus to regulate gene expression. Activation of WNT/β-catenin signaling inhibits β-catenin destruction, enabling translocation into the nucleus and expression of WNT/β-catenin target genes. HBM disorders affecting WNT/β-catenin signaling demonstrated that pathogenic variants in these HBM genes mostly result in an intense enhanced osteoblastic response. This may occur not only from pathogenic variants affecting receptor and ligand interactions, but also from variants coding for downstream intracellular components, with HBM also reported in individuals harboring damaging variants in *CTNNA1* (encoding β-catenin), *AMER1* (*WTX*), and *DVL1* (encoding Dishevelled) that can disrupt the cytoplasmic destruction of β-catenin.<sup>(23-25)</sup> In contrast, LoF pathogenic variants in *SFRP4*, encoding the WNT-sequestering protein sFRP4, were identified

in Pyle's disease (OMIM 265900), which is characterized by cortical thinning but increased trabecular bone mass.<sup>(26)</sup> These variants in *SFRP4* led to enhanced signaling in both the canonical and noncanonical arms of the pathway.

#### TGF- $\beta$ /BMP-SMAD signaling

HBM may also result from induced ossification, acting through components of the transforming growth factor  $\beta$  (TGF- $\beta$ ) and bone morphogenetic protein (BMP); these pathways are highly inter-linked by regulating phosphorylation of cytoplasmic SMAD transcription factors (henceforth called the TGF- $\beta$ /BMP-SMAD pathway) (Fig. 1). Pathogenic gain-of-function (GoF) variants in *TGFB1* or LoF variants in *LEMD3* and *SMAD9* activate the pathway and generally increase BMD. Moreover, somatic or acquired pathogenic variants affecting TGF- $\beta$ /BMP-SMAD signaling, ie, occurring during early developmental stages or in adult life, can be related to a HBM disorder characterized by a focal rather than generalized increase in ossification. For example, somatic GoF variants in *SMAD3* result in focal pathognomonic lesions of increased bone mass in the endosteal form of melorheostosis.<sup>(27)</sup> Sometimes these clinical aspects of melorheostosis are also detected in osteopoikilosis and dermatoosteopoikilosis (Buschke-Ollendorff syndrome; OMIM 166700), which are *LEMD3*-associated HBM disorders.<sup>(28)</sup> Typically, however, melorheostosis is caused by activating somatic variants in members of the rat sarcoma (RAS)-mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) pathway (*MAP2K1*, *KRAS*), leading to enhanced osteoblast proliferation.<sup>(29,30)</sup> These findings illustrate that pathways linked to basic cellular processes and which become dysregulated in, eg, oncogenesis, can also cause (mosaic forms of) HBM disorders.

#### Osteoblast differentiation

Besides osteoblast activity, pathogenic variants in genes encoding transcription factors that regulate osteoblast differentiation have also been identified as HBM genes. Pathogenic variants in *DLX3* and *SP7* (encoding Osterix) cause the HBM disorders tricho-dento-osseous dysplasia (OMIM 190320) and cranial hyperostosis with long bone fragility (OMIM n.a.), respectively (Fig. 1).<sup>(31,32)</sup> Because transcription factor activity is a multifaceted process, mutations in their corresponding genes can give a wide variety of phenotypes depending on their residual, hypomorphic, or neomorphic activities.

#### Bone resorption

Defects in bone resorption, from altered osteoclast recruitment, differentiation, or resorptive capacity, lead to osteopetrosis, manifest by thicker and/or more dense bones but with greater fragility predisposing to fracture.<sup>(33)</sup> A key role for the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B) signaling in osteoclast differentiation has been clearly illustrated by the osteoclast-poor forms of osteopetrosis, such as those caused by pathogenic variants in *TNFSF11* (RANKL; OMIM 259710),<sup>(34)</sup> *TNFRSF11A* (RANK; OMIM 612301, OMIM 224300),<sup>(35)</sup> or *IKBKG* (NEMO; OMIM 300291).<sup>(36)</sup> In contrast, osteoclast-rich forms of osteopetrosis may result from LoF variants in a large group of genes that affect osteoclast function by regulating bone matrix resorption (Fig. 1). For example, impaired function of the proteins encoded by *C11i*, *TCIRG1*, *CLCN7*, and *OSTM1* result in impaired acidification of the mineralized extracellular matrix (ECM).<sup>(37-41)</sup> Other pathogenic variants disturb protein-trafficking within the osteoclast, altering its ability to perform its resorptive function.

These HBM forms include *PLEKHM1*-related (OMIM 611497; OMIM 618107)<sup>(42,43)</sup> and *SNX10*-related osteopetrosis (OMIM 615085)<sup>(44)</sup> and dysosteosclerosis caused by *SLC29A3* mutations (OMIM 224300)<sup>(45)</sup> (Fig. 1).

These findings demonstrate that these pathways and processes are not only critical intersections in bone biology but also serve as mutational hotspots for HBM disorders. However, only a few genes have been thoroughly studied. Many of the genes that are poorly understood tend to be linked to (ultra)rare HBM conditions, which together will provide an attractive resource to discover new disease mechanisms.

#### Novel biological processes with anabolic potential for bone tissue

During the past decade, rapid progress in genetic screening technologies has enabled the identification of a larger variety of genes and biological processes linked to HBM. For example, pathogenic variants in genes encoding transmembrane transporters can cause HBM diseases but without necessarily causing extraskeletal manifestations. Damaging variants in *SLC39A14* and *ANO5*, both encoding transporters with a prominent function in osteoblasts, are responsible for HBM conditions hyperostosis cranialis interna (OMIM 144755)<sup>(14)</sup> and gnathodiaphyseal dysplasia (OMIM 166260), respectively.<sup>(46)</sup> Similarly for osteoclasts, mutations in *SLC29A3* and *SLC4A2* encoding respective nucleoside and anion transporters cause dysosteosclerosis (OMIM 224300)<sup>(45)</sup> and recessive osteopetrosis, Ikegawa type (OMIM n.a.) (Table S1).<sup>(47)</sup>

Interestingly, some HBM genes exert a significant role in the regulation of enzymatic activity, including the enzyme-encoding genes *COX4I2*, *PTDSS1*, and *DHCR24* associated with exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis (OMIM 612714), Lenz-Majewski hyperostotic dysplasia (OMIM 151050), and desmosterolosis (OMIM 602398), respectively.<sup>(48-50)</sup> Pathogenic variants in *HPGD* and *SLCO2A1*, encoding proteins involved in prostaglandin-related processes, are responsible for a recessive and dominant form of primary hypertrophic osteoarthropathy (OMIM 259100; 161700), respectively.<sup>(51)</sup> This illustrates that HBM genes belonging to the same group, and hence encoding proteins that regulate a similar biological process can result in similar phenotypes. Similarly, *POLR3B* and *POLR3GL* both encode for subunits of the DNA-directed RNA Polymerase III enzyme, and pathogenic variants in both genes cause HBM diseases characterized by endosteal hyperostosis (OMIM 614381; 619234).<sup>(52)</sup> Overall, these more unexpected biological processes harbor novel potential to increase bone mass.

#### Classification of HBM disorders according to their perturbed biological processes

As alluded in the previous section, HBM genes can be clustered based on shared biological functions (Fig. 1). For this review, we classified the 50 known HBM genes and their 59 associated disorders according to their established role in a signaling pathway and/or biological process (Table 1; Table S1). We used uniform Gene Ontology (GO) accession numbers (<http://geneontology.org/>) to create 10 distinct HBM (sub)groups. Moreover, GO identifiers were kept as broad as possible so that new genes can be added to existing HBM (sub)groups in the future (Table 1).

Some HBM groups are very evident: "Positive regulation of ossification" (GO:0045778, HBM group 1), containing key

**Table 1.** Classification of HBM Genes and Their Associated Disorders According to Biological Process and/or Pathway

| Biological process (GO accession number)/gene  | Disorder   | Inheritance | OMIM   | Nosology group |
|--|--|-------------|--------|----------------|
| <b>1. Regulation of ossification (GO:0030278) group</b>  |  |             |        |                |
| <b>1A. Regulation of Wnt signaling (GO:0008590) subgroup</b>   |  |             |        |                |
| <i>SOST</i>  | Sclerosteosis, type 1  | AR          | 269500 | 24             |
|  | van Buchem disease   | AR          | 239100 | 24             |
|  | Craniodiaphyseal dysplasia   | AD          | 122860 | 24             |
| <i>LRP4</i>  | Sclerosteosis, type 2  | AR, AD      | 614305 | 24             |
| <i>LRP5</i>  | Endosteal hyperostosis/Osteosclerosis  | AD          | 144750 | 24             |
| <i>LRP6</i>  | Generalized osteosclerosis   | AD          | n.a.   | n.a.           |
| <i>SFRP4</i>   | Metaphyseal dysplasia (Pyle's disease)   | AR          | 265900 | 24             |
| <i>DVL1</i>  | Robinow syndrome, with osteosclerosis  | AD          | 616331 | 17             |
| <i>AMER1</i>   | Osteopathia striata with cranial sclerosis   | XLD         | 300373 | 24             |
| <i>CTNBN1</i>  | Osteosclerosis and adrenocortical neoplasia  | AD/mosaic   | n.a.   | n.a.           |
| <b>1B. Regulation of TGF-<math>\beta</math>-BMP-SMAD signaling (GO:0017015) subgroup</b>                       |  |             |        |                |
| <i>TGF<math>\beta</math>1</i>  | Diaphyseal dysplasia (Camurati-Engelmann disease)                                    | AD          | 131300 | 24             |
| <i>LEMD3</i>   | Osteopoikilosis, with or without melorheostosis                                      | AD          | 166700 | 24             |
|  | Buschke-Ollendorff syndrome (dermatosteopoikilosis), with or without melorheostosis  | AD          | 166700 | 24             |
| <i>SMAD3</i>   | Melorheostosis, endosteal  | n.a.        | n.a.   | n.a.           |
| <i>SMAD9</i>   | Generalized osteosclerosis   | AD          | n.a.   | n.a.           |
| <i>TMEM53</i>  | Craniotubular dysplasia, Ikegawa type  | AR          | 619727 | n.a.           |
| <b>1C. Regulation of extracellular matrix assembly (GO:1901201) subgroup</b>                                   |  |             |        |                |
| <i>COL1A1</i>  | Infantile cortical hyperostosis (Caffey disease)                                     | AD          | 114000 | 22             |
| <i>FAM20C</i>  | Osteosclerotic bone dysplasia, lethal (Raine syndrome)                               | AR          | 259775 | 22             |
| <b>1D. Regulation of transmembrane transport (GO:0034762) subgroup</b>   |  |             |        |                |
| <i>SLC39A14</i>  | Hyperostosis cranialis interna   | AD          | 144755 | n.a.           |
| <i>ANO5</i>  | Gnathodiaphyseal dysplasia   | AD          | 166260 | 25             |
| <b>2. Regulation of osteoblast differentiation (GO:0045667) group</b>  |  |             |        |                |
| <i>DLX3</i>  | Tricho-dento-osseous syndrome  | AD          | 190320 | 24             |
| <i>SP7</i>   | Cranial hyperostosis and long bone fragility   | AD, dNO     | n.a.   | n.a.           |
| <b>3. Regulation of endochondral ossification (GO:0001958) group</b>   |  |             |        |                |
| <i>PTH1R</i>   | Blomstrand chondrodysplasia  | AR          | 215045 | 22             |
| <b>4. Regulation of bone resorption (GO:0045124) group</b>   |  |             |        |                |
| <b>4A. Regulation of vesicle-mediated transport (GO:0060627) subgroup</b>                                      |  |             |        |                |
| <i>PLEKHM1</i>   | Osteopetrosis, type OPTB6  | AR          | 611497 | 23             |
|  | Osteopetrosis, type OPTA3  | AD          | 618107 | 23             |
| <i>SNX10</i>   | Osteopetrosis, type OPTB8  | AR          | 615085 | 23             |
| <i>SLC29A3</i>   | Dysosteosclerosis  | AR          | 224300 | 23             |
| <b>4B. Regulation of extracellular matrix disassembly (GO:0010715) subgroup</b>                                |  |             |        |                |
| <i>CTSK</i>  | Pycnodysostosis  | AR          | 265800 | 23             |
| <i>TCIRG1</i>  | Osteopetrosis, type OPTB1  | AR          | 259700 | 23             |
| <i>CA2</i>   | Osteopetrosis, type OPTB3  | AR          | 259730 | 23             |
| <i>CLCN7</i>   | Osteopetrosis, type OPTB4  | AR          | 611490 | 23             |
|  | Osteopetrosis, type OPTA2  | AD          | 166600 | 23             |
| <i>OSTM1</i>   | Osteopetrosis, type OPTB5  | AR          | 259720 | 23             |
| <i>SLC4A2</i>  | Osteopetrosis, Ikegawa type  | AR          | n.a.   | n.a.           |
| <i>ANKH</i>  | Cranio-metaphyseal dysplasia   | AD          | 123000 | 24             |
| <i>LRRK1</i>   | Osteosclerotic metaphyseal dysplasia   | AR          | 615198 | 23             |
| <b>5. Regulation of osteoclast differentiation (GO:0045670) group</b>  |  |             |        |                |
| <b>5A. Regulation of I-<math>\kappa</math>B kinase/NF-<math>\kappa</math>B signaling (GO:0043122) subgroup</b> |  |             |        |                |
| <i>TNFSF11</i>   | Osteopetrosis, type OPTB2  | AR          | 259710 | 23             |
| <i>TNFRSF11A</i>   | Osteopetrosis, type OPTB7  | AR          | 612301 | 23             |
|  | Dysosteosclerosis  | AR          | 224300 | 23             |
| <i>TNFRSF11B</i>   | Juvenile Paget's disease   | AR          | 239000 | 24             |
| <i>SQSTM1</i>  | Paget's disease of bone  | AD          | 167250 | n.a.           |
| <i>VCP</i>   | Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 | AD          | 167320 | n.a.           |

(Continues)

**Table 1.** Continued

| Biological process (GO accession number)/gene  | Disorder   | Inheritance | OMIM   | Nosology group |
|--|--|-------------|--------|----------------|
| <i>IKBKG</i>   | Osteopetrosis, with lymphedema, ectodermal dysplasia, anhidrotic, and immunodeficiency (OLEDAID) | XLR         | 300291 | 23             |
| 5B. Regulation of macrophage colony-stimulating factor signaling pathway (GO:1902226) subgroup |  |             |        |                |
| <i>CSF1R</i>   | Dysosteosclerosis, brain abnormalities, neurodegeneration  | AR          | 618476 | 23             |
| 6. Regulation of cell adhesion (GO:0030155) group  |  |             |        |                |
| <i>GJA1</i>  | Craniometaphyseal dysplasia  | AR          | 218400 | 24             |
|  | Oculodentoosseous dysplasia, mild type   | AD          | 164200 | 24             |
|  | Oculodentoosseous dysplasia, severe type   | AR          | 257850 | 24             |
| <i>FERMT3</i>  | Osteopetrosis with defective leukocyte adhesion  | AR          | 612840 | 23             |
| 7. Regulation of prostaglandin metabolism or transport (GO:0001516; GO:0015732) group          |  |             |        |                |
| <i>TBXAS1</i>  | Ghosal hematodiaphyseal dysplasia  | AR          | 231095 | 24             |
| <i>HPGD</i>  | Primary hypertrophic osteoarthropathy  | AR          | 259100 | 24             |
| <i>SLCO2A1</i>   | Primary hypertrophic osteoarthropathy  | AD          | 167100 | 24             |
| 8. Regulation of catalytic activity (GO:0050790) group   |  |             |        |                |
| <i>COX4I2</i>  | Calvarial hyperostosis, with pancreatic insufficiency and dyserythropoietic anemia               | AR          | 612714 | n.a.           |
| <i>PTDSS1</i>  | Lenz-Majewski hyperostotic dysplasia   | AD          | 151050 | 24             |
| <i>DHCR24</i>  | Desmosterolosis  | AR          | 602398 | 22             |
| 9. Regulation of RAS-MAPK-ERK signaling (GO:0046578; GO:0043408) group                         |  |             |        |                |
| <i>MAP2K1</i>  | Melorheostosis, isolated, somatic mosaicism  | n.a.        | 155950 | 24             |
| <i>KRAS</i>  | Melorheostosis, isolated, somatic mosaicism  | n.a.        | n.a.   | n.a.           |
| 10. Regulation of RNA Polymerase III activity (GO:1903622) group                               |  |             |        |                |
| <i>POLR3B</i>  | Cerebellar hypoplasia with endosteal hyperostosis  | AR          | 614381 | 24             |
| <i>POLR3GL</i>   | Short stature, oligodontia, dysmorphic facies, and motor delay with endosteal sclerosis          | AR          | 619234 | n.a.           |

AD = autosomal dominant; AR = autosomal recessive; DN = dominant negative; dNO = de novo; GO = Gene Ontology; HDM = high bone mass; n.a. = not available; OMIM = Online Mendelian Inheritance in Man; XLD = X-linked dominant; XLR = X-linked recessive.

pathways such as “Regulation of Wnt signaling” (GO:0008590, subgroup 1A) and “Regulation of TGF- $\beta$ -BMP-SMAD signaling” (GO:0017015, subgroup 1B). Similarly, genes involved in the “Regulation of bone resorption” were also grouped (GO:0045779, HBM group 4). Smaller HBM groups so far contain the poorly understood HBM genes (eg, *COX4I2*, *GJA1*, *FERMT3*, *PTDSS1*) involved in processes such as “Regulation of cell adhesion” (GO:0030155, HBM group 6) and “Regulation of enzymatic catalytic activity” (GO:0050790, HBM group 8).

We believe that this classification based on biological function (Table 1) can complement the existing and more clinically-based classification of all genetic skeletal disorders by the International Skeletal Dysplasia Society (ISDS) and may help in determining the genetic background and subsequent clinical approach for certain HBM phenotypes.<sup>(53)</sup> Identification of new HBM genes within the known subgroups could help in further functional characterization or may create new subgroups when novel biological processes are associated with HBM.

## Understanding HBM Mechanisms through Functional Genomics


Forward genetic approaches (from phenotype to genotype) have been the main driver of our molecular and functional understanding of HBM disorders. Substantial technological developments now allow larger-scale testing of molecular pathways on a systems level; ie, through functional genomics. This means that a “reverse genetic” approach is now feasible, where a genotype is used to understand the molecular and metabolic

makeup of skeletal phenotypes (Fig. 2A). By deploying such an approach, one can reveal molecular, regulatory, and genetic networks and mechanisms that are dysregulated due to the genetic defect causing HBM.

## Omic technologies as a basis in functional genomics

In the era of omics, the wide array of available in vitro and in vivo model systems provide functional genomics tools to scrutinize HBM disease pathways. Omics allow capturing the molecular architecture of a cell or a tissue in its entirety in a “hypothesis-free” setting. Those in-depth profiles of a “biological activity” (eg, via transcriptomics [RNA expression], proteomics [protein abundance], or metabolomics [enzymatic activity of proteins]) can be linked to available genomic and epigenomic datasets that perhaps could be described as “functional potential” data. The combined output can then show that certain “functional predictions” (ie, genetic variants, and/or histone methylation) are indeed regulating a biological activity involving HBM pathophysiology.<sup>(54,55)</sup>

A few important notes should be considered regarding the complex tissue of bone: (i) bone contains many different cell types; (ii) it is relatively time-consuming and difficult to acquire bone tissue from affected cases/controls, or from in vivo models; (iii) bone has major two forms of formation (intramembranous or endochondral ossification); and (iv) each bone element has a unique location/microenvironment in the skeleton which may be subject to its own unique gene expression and protein composition signature. These practical issues provide a (partial)



**Fig. 2.** Overview of forward versus reverse genetics and functional genomics tools for HBM research. (A) the forward and reverse genetic research cycle to discover new genes with HBM causing variants allowing to solve genetically unexplained HBM cases in the clinic. (B) The functional genomic toolbox at the disposal of basic and translational health scientists encompassing, but not limited to 2D and 3D *in vitro* models, mouse and rats, and zebrafish. The + stands for more advantageous and – for more disadvantageous relative to the other common model systems used in the field. HBM = high bone mass.

explanation why there have been relatively few bone omic studies involving HBM published in the past few years (Table 2).

The overarching strength of omics is that they widely capture “biological activity” and create molecular systems or signatures that reflect certain disease states. Transcriptome technologies, such as microarray hybridization technology and RNA-sequencing (RNAseq) are used most frequently in the HBM field (Table 2). In recent years, RNAseq of isolated tissue (bulk RNAseq) or single cells isolated from a tissue (scRNAseq) have been more widely deployed and allow to capture the spatiotemporal expression profile or a comparison of control versus disease/treatment. scRNAseq especially generates complex profiles that define distinct cell populations in an unbiased way. This allows exploration of mechanisms caused by minority cell populations or by changes in the proportion of bone lineages, which can be hidden in a bulk strategy. These transcriptional signatures of cell populations can therefore reveal the heterogeneity,<sup>(95)</sup> even after fluorescence-activated cell sorting (FACS).

Although transcriptomic studies are one strategy to explore pathological changes in bone cells or tissue, other mechanisms may be better studied by proteomic, epigenomic, and/or

metabolomic approaches; eg, processes that involve cellular stress, transcription factor binding, or environmentally induced HBM after exposure to excessive levels of sodium fluoride (skeletal fluorosis).<sup>(96)</sup> These less common omic strategies are yet to be conducted widely in bone, but they have great potential.

The available model systems and methods of in-depth phenotyping to study bone mass have been extensively reviewed previously by the GEMSTONE working groups and others.<sup>(3,4,97-99)</sup> Here, we primarily focus on the state-of-the-art in key lab-based model systems and the potential of combining multiple omic assessments in multiple model systems for the HBM field.

### State-of-the-art functional genomics approaches

#### 2D *in vitro* cultures

2D monocultures and co-cultures of bone cell types are a common means of generating functional data rapidly to understand various genetic consequences (Fig. 2B). Such cultures allow read-outs of, eg, cell metabolism, ECM formation, and subcellular localization of proteins, which is difficult to capture *in vivo*.<sup>(100-105)</sup> For



**Table 2.** Overview of Omic Studies and Investigated Biological Processes That Can Model Characteristics of Bone Anabolism in the Main Model Systems

| Omic       | Method               | Species             | Tissue or cell type | Bulk or Sc | Genotype and/or conditions  | Process                                   | Highlighted pathways, regulatory nodes, and/or group of factors                         | Citation |
|------------|----------------------|---------------------|---------------------|------------|---|---|---|----------|
| T          | Microarray           | Human               | Mcy                 | Bulk       | H/L-BMD   | Oc differentiation                        | RIG-I like receptor, fatty acid metabolism  | (56)     |
| T          | Microarray           | Human               | MSC, Ob             | Bulk       | Co-culture  | Ob differentiation                        | Collagen synthesis, BMP pathway   | (57)     |
| T          | RNAseq               | Human               | Ob                  | Sc         | osteoarthritis and osteopenia   | Gene expression during disease            | NR4A2/1, COL1A1, SPARC, RUNX2, BGALP, VCAM1, LEPR                                       | (58)     |
| T          | RNAseq               | Mouse               | BM Adpc             | Bulk       | <i>Ddr2<sup>fl/fl</sup>;Adipoq-Cre</i>                                  | GPCR signaling                            | Adcy5-cAMP-PKA signaling  | (59)     |
| T          | RNAseq               | Mouse               | Ob                  | Bulk       | <i>Lrp5<sup>fl/fl</sup>;Lrp6<sup>fl/fl</sup>;UBC-Cre-ER<sup>2</sup></i> | Wnt3a and LRP5/6 signaling                | WNT signaling, TGF- $\beta$ signaling, MAPK signaling, ECM organization, focal adhesion | (60)     |
| T          | Microarray           | Mouse               | Mcy, Oc             | Bulk       | <i>Nfatc1<sup>fl/fl</sup>;Mx1-Cre</i>                                   | Oc differentiation                        | Calcineurin, Rankl, bone resorption   | (61)     |
| T          | RNAseq               | Mouse               | Ob                  | Sc         | <i>R26R-Lyn-Venus; Col1a1-Cre</i>                                       | Ob differentiation                        | Cdc34, Cxcl12, Dlx5, Sost, Sp7  | (62)     |
| T          | RNAseq               | Mouse               | Adpc                | Bulk       | <i>iDTR<sup>fl/fl</sup>;Adipoq-Cre</i>                                  | Dynamics between Adpc and Ob              | BMP signaling, IGF signaling, ECM synthesis   | (63)     |
| T          | RNAseq               | Mouse               | Ob                  | Bulk       | <i>Cdc73<sup>fl/fl</sup>;Ocn-Cre</i>                                    | Bone remodeling                           | MAPK signaling, collagen processing   | (64)     |
| T          | Microarray           | Mouse               | Ob                  | Bulk       | <i>Lrp5<sup>fl/fl</sup>;Ocn-Cre</i>                                     | Fatty acid metabolism                     | Ob differentiation, fatty acid synthesis  | (65)     |
| T          | Microarray           | Mouse               | Ocy454              | Bulk       | WT  | High vs. low Sost expressing sub-clones   | Carbonic anhydrase, oxidative stress  | (66)     |
| T          | Microarray           | Mouse               | Ocy                 | Bulk       | <i>ER<math>\alpha</math><sup>fl/fl</sup>;Dmp1-Cre</i>                   | ER $\alpha$ signaling                     | Secreted (glyco)proteins, ECM, sost1dc  | (67)     |
| T          | Microarray           | Mouse               | Cortical WBE        | Bulk       | <i>Phex<sup>-/-</sup></i>   | Fgf23 production and mineralization       | CA pathway, ECM synthesis, BMP signaling, IGF signaling, cell adhesion                  | (68)     |
| T          | RNAseq               | Mouse               | Skull WBEs          | Bulk       | <i>Twist1<sup>+/-</sup></i>   | Osteogenesis                              | Fgf23, bone mineralization  | (69)     |
| T          | RNAseq               | Mouse               | SPC                 | Sc         | WT, Rosiglitazone, irradiation, fracture                                | SPC differentiation: Ob and Adpc dynamics | Notch signaling, Cathepsin K, Twist1, Atf4, Klf4, Hoxb2, Npdc1, Mef2c                   | (70)     |
| T          | RNAseq               | Mouse               | Endochondral WBE    | Sc         | WT, fracture healing  | MSC derived Septoclasts                   | Proteoglycans, MMP, Notch signaling, cell-matrix interactions                           | (71)     |
| T          | Microarray           | Mouse               | Endochondral WBE    | Bulk       | <i>p27<sup>-/-</sup></i>  | Ob differentiation                        | Sonic Hedgehog-Gli-Bmi1 signaling, p130-E2F4  | (72)     |
| T          | RNAseq               | Mouse               | WBE, Oc, VT         | Bulk       | <i>Cln3<sup>G213R</sup></i>   | Osteopetrosis, type OPTA2                 | JAK-STAT signaling, cytokine, hematopoiesis   | (73)     |
| T          | RNAseq, GSA          | Mouse & Human       | Ocy                 | Bulk       | WT  | Bone homeostasis                          | WNT signaling, BMP signaling, ECM organization, angiogenesis, axon development          | (74)     |
| T          | RNAseq               | Mouse, rat, macaque | Ocy                 | Bulk       | WT  | Cross-species regulation of bone healing  | Regulation of bone remodeling and BMD   | (75)     |
| T          | Microarray           | Rat                 | Calvaria WBE        | Bulk       | WT  | Bone healing                              | Focal adhesion, ECM-receptor interaction, TNF signaling, Hippo signaling                | (76)     |
| T          | Microarray           | Zebrafish           | CF                  | Bulk       | WT  | Ob differentiation                        | ECM synthesis, WNT signaling, SMAD-BMP signaling  | (77)     |
| T          | RNAseq               | Medaka              | Ob, CF              | Bulk       | <i>rank1:HSE:CFP</i>  | Oc and Ob differentiation                 | ECM degradation, MMP, ECM-receptor interactions, cell cycle                             | (78)     |
| T          | RNAseq               | Zebrafish           | CNCC                | Sc         | WT  | Craniofacial development                  | WNT signaling, FOXD, v-ATPases  | (79)     |
| T, Met, Mu | Microarray, meDIPseq | Human               | BMSC                | Bulk       | H/L-BMD   | BMSC differentiation                      | MicroRNAs, AKT-STAT signaling, FAM50A, ZNF473, TMEM55B, FLT3                            | (80)     |

(Continues)

**Table 2.** Continued

| Omic      | Method             | Species      | Tissue or cell type | Bulk or Sc | Genotype and/or conditions                            | Process  | Highlighted pathways, regulatory nodes, and/or group of factors                                  | Citation |
|-----------|--------------------|--------------|---------------------|------------|---|--|--|----------|
| T, E, Met | RNAseq, Wgmetseq   | Human        | iPSCs               | Bulk       | CLCN7 <sup>R286W</sup>                                | Osteopetrosis, type OPTA2, transcriptional programming | TNF signaling, Ras signaling, FOXO   | (81)     |
| T, G      | RNAseq, GWAS       | Mouse, Human | BMSC                | Sc         | Cxcl12-eGFP and <i>Rspo3<sup>fl/fl</sup>;Runx2Cre</i> | BMSC differentiation                                   | Proteasomal degradation of WNT receptors   | (82)     |
| T, G      | RNAseq, GWAS       | Mouse, Human | Cortical WBE        | Bulk       | WT  | Aging  | PI3K-AKT signaling, focal adhesion, cell adhesion, ECM synthesis, WNT signaling, TGF-β signaling | (83)     |
| T, G      | RNAseq, GSA        | Zebrafish    | ES                  | Bulk       | WT  | Ob differentiation                                     | Collagen processing, ECM synthesis, focal adhesion, hedgehog signaling, IGF signaling            | (84)     |
| T, E      | RNAseq, ATACseq    | Human        | CF                  | Bulk       | WT  | Ob differentiation                                     | Cell cycle process, ECM organization, cholesterol biosynthesis                                   | (85)     |
| T, E      | RNAseq, snATACseq  | Zebrafish    | CNCC                | Sc         | WT  | CNCC differentiation during lifespan                   | ECM organization, BMP signaling, WNT signaling, NFAT, RUNX, CXCL12                               | (86)     |
| T, P, Mb  | RNAseq, LC-MS/MS   | Zebrafish    | CF                  | Bulk       | WT  | Ob differentiation                                     | Retinoic acid, WNT signaling, FGF signaling  | (87)     |
| P         | LC-MS/MS           | Human        | Ob, BMSC            | Bulk       | Dexamethasone and hyaluronic acid                     | Ob-released matrix vesicles                            | ECM synthesis, Integrin, PPAR $\gamma$ , CXCR4, MAPK-ERK signaling, EIF2                         | (88)     |
| P         | LC-MS/MS           | Zebrafish    | CF                  | Bulk       | Prednisolone  | Ob differentiation                                     | ECM synthesis, focal adhesion, ion binding, secretory pathway                                    | (89)     |
| P         | MS                 | Zebrafish    | WBE, CF             | Bulk       | WT  | Bone maturation and aging                              | ECM synthesis, WNT signaling   | (90)     |
| P         | LC-MS/MS, MALDI-MS | Zebrafish    | CF                  | Bulk       | WT  | Ob differentiation                                     | Focal adhesion, regulation of Actin cytoskeleton   | (91)     |
| P         | MALDI-MS           | Zebrafish    | CF                  | Bulk       | WT  | Ob differentiation                                     | Focal adhesion, immune response, cytoskeleton  | (92)     |
| G         | GWAS               | Mouse        | Som                 | WG         | WT  | Aging  | Osteoblast differentiation, BMP signaling  | (93)     |
| Mb        | NMR                | Human        | Serum               | Bulk       | Unexplained HBM                                       | Bone turnover markers                                  | β-C-terminal telopeptide of type-I collagen, citric acid   | (94)     |

Adpc = adipocyte; ATACseq = assay for transposase accessible chromatin sequencing; BMSC = bone marrow stem cell; (H/L)BMD = (high/low) bone mineral density; CA = carbonic anhydrase; CF = caudal fin; CNCC = cranial neural crest cell; DTR = diphtheria toxin receptor; E = epigenomic; ECM = extracellular matrix; ER $\alpha$  = estrogen-receptor  $\alpha$ ; *fl/fl*; *flox/flox*; G = genomic; GPCR = G-protein coupled receptor; GSA = gene set analysis; GWAS = genome-wide association study; IGF = insulin-like growth factor; LC-MS = liquid chromatography-mass spectrometry; MALDI = matrix-assisted laser desorption/ionization; Mb = metabolomic; Mcy = monocyte; Met = methylomics; MS = mass spectrometry; MSC = mesenchymal stem cell; Mu = MicroRNAomic; NMR = proton nuclear magnetic resonance spectroscopy; Ob = osteoblast; Oc = osteoclast; Ocy = osteocyte; P = proteomic; RNAseq = RNA-sequencing; Sc = single-cell; Sn = single-nucleus; Som = somatic; SPC = skeletal progenitor cell; T = transcriptomic; VT = visceral tissue; WBE = whole-bone element; WG = whole-genome; Wgmetseq = whole-genome methylation sequencing; WT = wild-type.

this purpose, various cell lines for all bone cell types have been created and have been extensively reviewed.<sup>(106-109)</sup> As an example pertinent to the study of HBM, the Ocy454 cell line is a *Dmp*-positive (*Dmp*<sup>+</sup>) osteocytic cell line that expresses elevated levels of *Sost*, making it a model to study the effects of mechanical loading.<sup>(105)</sup>

Transcriptome microarray profiling revealed *CA3* (encoding carbonic anhydrase III) as a novel marker of differentiated osteocytes in high *Sost*-expressing clones, next to typical markers such as *Dmp1* and *Phex*. This led to the understanding that *CAIII* protects osteocytes from oxidative stress.<sup>(66)</sup> Interestingly, expression studies also demonstrated that sclerostin induces *CA2* (encoding carbonic anhydrase II) to regulate bone mineral release in MLO-Y4 cells, another osteocytic cell line.<sup>(100)</sup> This shows that genes coding for enzymes, like carbonic anhydrases, can unexpectedly be important for cells from the mesenchymal lineage. One good example is *CA2*, traditionally classified as an osteoclast gene harboring mutations causal for a severe form of osteopetrosis (OMIM 259730).

### Rodent models

Mouse and rat models have been widely used as an in vivo model for the human skeletal system. They possess all the relevant skeletal cell types, types of bone, and genes between humans and rodents have high homology (Fig. 2B).<sup>(106)</sup> Mouse models have delivered great successes in bone research, for example in deciphering the WNT/ $\beta$ -catenin and NF- $\kappa$ B pathways, by using cellular and dynamic histomorphometric methods, three-point bending assays, as described.<sup>(3,110,111)</sup> Here, we report a list of 56 transgenic mouse models for 22 known HBM genes and intriguingly, an additional 80 transgenic mouse models covering 56 genes, in which no pathogenic variants have been identified in humans with a form of HBM so far (Table S2). We also identified 20 studies that used mouse-derived or rat-derived bone tissue for omic assessments to model aspects of HBM (Table 2).

Recently, another study using bulk RNAseq characterized an “osteocyte transcriptome signature” (OTS) (Table 2) using sequence data from bone matrix-embedded cells with high *Sost* expression. Genes that have a highly enriched expression in osteocytes included many associated with skeletal diseases (such as osteogenesis imperfecta and sclerosteosis) and were often associated with common skeletal diseases (such as osteoporosis and osteoarthritis).<sup>(74)</sup> Moreover, the study showed that the OTS dynamically changes during skeletal maturation and is sex dependent. The OTS will provide a powerful resource of reference osteocyte genes for future HBM studies. Bulk RNAseq approaches also allow identifying novel regulatory mechanisms yet not associated with HBM, as is demonstrated with *Wnt3a* dynamically interacting with the *Lrp5* and *Lrp6* receptors to alter *Wnt* signaling pathway activation.<sup>(60)</sup>

In mice, an scRNAseq approach on FACS *Col1a1*-expressing (*Col1a1*<sup>+</sup>) cells explored the concept of osteoblast heterogeneity. Functional annotation resulted in the identification of four clusters; ie, clusters 1–3 captured active bone-forming osteoblasts in different maturational stages whereas cluster 4 captured fewer active osteoblasts with progenitor properties.<sup>(62)</sup> Biological processes most significantly enriched in these clusters were positive regulation of cell cycle (cluster 1; GO:0045787), endochondral ossification (cluster 2; GO:0001958), chondrocyte differentiation (cluster 3; GO:0002062), and cell adhesion mediated by integrin (cluster 4; GO:0033627).<sup>(62)</sup> A similar strategy

was also deployed to understand the role of fracture risk factor *RSPO3* in mesenchymal skeletal stem cell populations fine tuning osteoblastic and adipogenic cell fates.<sup>(82)</sup> Recently, an scRNAseq assessment also identified cartilage and noncalcified bone matrix resorbing cells, called septoclasts, predominantly located at the chondro-osseous border, which are derived from nonhematopoietic lineages but express *Ctsk* and *Fabp5*.<sup>(71)</sup> Importantly, septoclasts were also involved in fracture repair of endochondral bone. These studies showed that scRNAseq is an extremely valuable tool to find mechanisms and new cell populations that are difficult to capture.

Finally, osteoclasts from the *Clcn7*<sup>G213R</sup> mouse model with autosomal dominant osteopetrosis (OMIM 166600) have also been analyzed with bulk RNAseq.<sup>(73)</sup> Biological processes enriched in *Clcn7*<sup>G213R</sup> osteoclasts included response to stimulus (GO:0050896), extracellular matrix organization (GO:0030198) and cell adhesion (GO:0007155), whereas underrepresented processes included RNA processing (GO:0006396), messenger RNA (mRNA) processing (GO:0006397) and cellular response to DNA damage stimulus (GO:0006974). Bulk RNAseq of other tissues affected in osteopetrosis patients (eg, brain, kidney, liver) was also performed to uncover biomarkers for follow-up of *CLCN7*-related osteopetrosis patients in future experimental clinical trials.<sup>(73)</sup>

## Emerging functional genomics model systems

### 3D modeling of bone tissue in vitro

One of the holy grails in the bone field is to accurately mimic bone's in vivo complexity in a controlled in vitro laboratory setting. Beyond advancing scientific knowledge per se, this would enable refinement, reduction, and replacement of animals in research (3Rs principle). Although indirect, transwell, and/or direct co-cultures of osteoblasts, osteocytes, and osteoclasts have been widely used, these approaches can be challenging; eg, they often require complex matrix coatings.<sup>(112,113)</sup> To address this, organoids and three-dimensional (3D) tissue culture strategies have been proposed. Recently, two exciting organoid systems have been developed with relevance for the HBM field. An organoid of woven bone can track the differentiation process from bone marrow-derived stem cells (BMSCs) to osteocytes in a silk fibroin scaffold-based 3D setting. New mineralized collagen matrix was visualized with advanced electron microscopy techniques showing remarkable similarities with woven bone in situ.<sup>(114)</sup>

Second, an organoid of trabecular bone was derived from mesenchymal stromal cells separated by spacers, in a demineralized bone paper scaffold-based 3D environment; the spacers then allowed exposure to osteoclasts, thus replicating bone remodeling in vitro.<sup>(115)</sup> As an example in HBM, such in vitro tissue engineering approaches have been used to study osteopetrosis caused by LoF *TNFSF11* (*RANKL*) mutations in *Rankl*<sup>-/-</sup> mice.<sup>(116,117)</sup> These culture systems are often derived from induced pluripotent stem cells (iPSCs), or from BMSCs harvested from consented patients, with subsequent differentiation into skeletal cell types.<sup>(118,119)</sup> However, iPSCs derived from individuals with genetically unexplained HBM could also be used to gain mechanistic insights into the cellular and molecular causes of their disease. Thus, organoids have immense potential, but are still to be established as a common methodology, at least in part due to expense; currently costing ~US\$1000 per culture,

though likely to fall with increased use and protocol refinement (Fig. 2).<sup>(120,121)</sup>

### Fish models

Zebrafish (*Danio rerio*), or occasionally medaka fish (*Oryzias latipes*), are also used to model human diseases. They are relatively cheap to house, amenable to genetic and pharmacological manipulation, and accessible for skeletal imaging (Fig. 2B).<sup>(122)</sup> More than 85% of human disease causing genes have orthologues in zebrafish and their skeletal physiology shows strong similarities to mammals.<sup>(123)</sup> Their mineralized endoskeleton also responds to *sost*-regulated remodeling after loading.<sup>(124,125)</sup> Adult zebrafish also have a mineralized exoskeleton that enables *ex vivo* tracking of bone regeneration and healing.<sup>(126)</sup> To date, there is a vast library of transgenic reporter and mutant zebrafish available that has been shown to accurately model various skeletal diseases (Zebrafish Information Network [ZFIN]; [www.zfin.org](http://www.zfin.org)), allowing bone cell populations to be imaged, FACS isolated, or manipulated.<sup>(124,127,128)</sup> Zebrafish can also model high BMD<sup>(84,129-131)</sup>; eg, an osteopetrosis-like phenotype in *mmp9*<sup>-/-</sup>; *mmp13b*<sup>-/-</sup> double mutant fish,<sup>(78)</sup> *CSF1R*-related dysosteosclerosis (OMIM 618476),<sup>(132,133)</sup> and *PTDSS1*-related Lenz-Majewski hyperostotic dysplasia (OMIM 151050).<sup>(134)</sup>

### Exploiting the zebrafish lifespan to understand spatiotemporal and molecular causes of HBM

Initial zebrafish development is rapid with the first skeletal progenitor cells in the form of neural crest cells appear around the first day of development. During neural crest cell migration, cranial neural crest cell (CNCC) progenitors form parts of the craniofacial skeleton.<sup>(132,135)</sup> Neurocristopathies are a group of disorders where the migration of neural crest cells is perturbed, which can affect many tissues, including skeletal elements in the face and jaw, teeth, bone marrow (hematopoietic lineage), and ears.<sup>(136)</sup> Additionally, neural crest cells are a multipotent cell population and its migration is also pivotal for proper neurological, pigment, heart, and sensory development.<sup>(137,138)</sup> Some HBM disorders with significant craniofacial involvement have characteristics of neurocristopathies, such as the mandible enlargement seen in van Buchem disease patients. Similarly, Lenz-Majewski hyperostosis, gnathodiaphyseal dysplasia, Robinow syndrome, and desmosterolosis lie within the neurocristopathy spectrum. *DLX3* is also a well-known factor in neural crest cells of which mutations result in tricho-dento-osseous syndrome (Table 1).<sup>(139)</sup> Because neural crest migration and their derivatives can be visualized both in real time and throughout the zebrafish lifespan, there is a great potential to fundamentally understand the early processes underlying these disorders.

An scRNAseq approach showed transcriptional heterogeneity among CNCCs with distinct cell populations committed to become skeletal progenitors, melanocytes, or neuronal glial cells.<sup>(79)</sup> Another study linked transcriptomic and epigenomic datasets focused on longitudinal specification and diversification potential of single CNCCs fate throughout the zebrafish lifespan.<sup>(86)</sup> With a single-nuclei assay for transposase accessible chromatin sequencing (snATACseq) and scRNAseq technologies it is possible to match chromatin accessibility (potential for activity) with gene expression (activity) in single cells during cell type differentiation.<sup>(86)</sup> Using omic approaches could provide a fundamental understanding of the dysregulated gene networks during CNCC migration and cell differentiation in zebrafish

mutants of HBM with neurocristopathological elements<sup>(136)</sup> or poorly studied multitissue disorders (ie, HBM group 8, Table 1).

SMAD9, encoded by the HBM gene *SMAD9*, is mostly known for as a BMP-signaling transcriptional inhibitor.<sup>(140)</sup> Studying Smad9 in zebrafish uncovered that *smad9* inhibits osteochondral precursor differentiation, which responded to pharmacological treatment.<sup>(141)</sup> Zebrafish skeletons continue growing throughout life, enabling facets of growing bone to be tracked in living fish over time, as demonstrated by the impaired formation of calvarial sutures in *sp7*-deficient zebrafish.<sup>(142,143)</sup> Proteomics of the acellular ECM of bone from skull, axial, and exoskeletal fin rays from different developmental stages showed that ECM synthesis proteins were abundant at all stages and that endochondral ossification proteins became less abundant with age whereas proteins involving ECM synthesis increased their relative abundance.<sup>(90)</sup> Following the growth and maturation of bone in an adult *in vivo* setting is difficult in other model systems (Fig. 2B).

The zebrafish exoskeleton allows studying osteoanabolism in an adult setting

As mentioned in the introduction on fish models, zebrafish have a mineralized exoskeleton formed through dermal ossification, consisting of fin rays and scales that harbor osteoblasts and osteoclasts. These fins and scales can fully regenerate *ex vivo* by making new ECM from *de novo* differentiated osteoblasts. With the availability of fluorescent reporter lines, this regeneration process can be followed without sacrificing the fish. This allows longitudinal studies of osteoanabolism exceeding osteocatabolism. Omic studies using fin regeneration have mostly focused on the early regeneration stages (Table 2). During its initial stages factors involved in focal adhesion and ECM synthesis pathways are often enriched (Table 2). For example, a proteomic study of early regenerating fins from fish treated with prednisolone showed that proteins involved in ossification (GO:0001503), lysosomal lumen acidification (GO:0007042), ion transport (GO:0006811), the secretory pathway (GO:0045054), and vesicular transport (GO:0016192) were changed.<sup>(89)</sup>

The regenerating scale has not been intensively studied, even though scales are abundant, easily accessible, and can be cultured *ex vivo* in a multiwell setting. They have distinct landmarks from the rims with growing mineralized matrix, housing early osteoblasts, to the center of the scale where late osteoblasts reside. A recent study using bulk RNAseq on regenerating scales showed an enrichment of differentially expressed genes linked to ossification (GO:0001503), hedgehog/smoothed signaling pathway (GO:0007224), insulin-like growth factor signaling (GO:0048009), and cell adhesion (GO:0007155).<sup>(84)</sup> Moreover, many genes involved in a regenerating scale were enriched for human orthologues that cause monogenic skeletal diseases (eg, *COL1A1*-, *SP7*-, *ANOS*-related osteogenesis imperfecta) and/or are in loci associated with polygenic bone traits (eg BMD, height).<sup>(84)</sup>

## Shortening the Diagnostic Timeframe for HBM Disorders in the Future

The future wave of strategies and technologies to improve HBM gene discovery

Despite the major advances in genomic knowledge and genetic testing, affected individuals often end up in an unsolved or “discovery cohort,” where a novel molecular mechanism is expected

to underlie the development of an (un)known HBM phenotype. The remaining challenge in the diagnostics of HBM disorders, therefore, is how best to identify and characterize novel HBM genes, both time- and cost-effectively.

Although most gene discovery to date has arisen from WES, a shift toward WGS will enable researchers to expand beyond exonic variation to assess splicing variants, larger insertions or deletions (InDels), chromosomal rearrangements and repeat expansions (copy number variation), which may uncover novel disease mechanisms. In the case of larger chromosomal abnormalities, alternative detection methods can be used, such as single-nucleotide polymorphism (SNP) arrays, array comparative genomic hybridization (aCGH), or long-read sequencing.<sup>(144)</sup> Additionally, mosaic HBM disorders (eg, melorheostosis) may require deep genomic sequencing with read depth of hundreds to thousands, because fewer cells carry the pathogenic variant of interest.<sup>(145)</sup> Defects in gene regulation, as in van Buchem disease cases, are often not yet picked up in a clinical setting. The combined use of WGS and RNAseq (eg, on differentiated iPSCs) could improve the identification of splicing mutations or regulatory DNA mutations (promoter regions, enhancers).

After determining the pathogenicity of variants in accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines, evaluating variants of uncertain significance (VUS), coding or noncoding, for their causality remains challenging.<sup>(146)</sup> Interpretation of substantial amounts of VUS, even after variant filtering, can be extremely time-consuming. Often, at this stage, larger gene panels are used, for example including all genes listed in the latest ISDS nosology.<sup>(53)</sup> This strategy, however, includes variation in >400 genes related to an immense variety of skeletal phenotypes. Alternatively, VUS linked to the >500 genes or loci listed in genomewide association studies (GWASs) for their association with variance in BMD (as derived from DXA) may be used as a prioritization tool, but often still leaves scientists and clinicians puzzled with a lengthy list.<sup>(147,148)</sup> GWAS-associated variants also tend to have a small contribution, ie, individually, to the variance in BMD whose biological impact may be different from the processes disturbed by rare variants underlying a HBM disorder. Nevertheless, (few) individuals at the high extreme of the BMD polygenic score distribution can mimic the presence of a monogenic mutation, without harboring one.<sup>(149,150)</sup> Finally, BMD is subject to substantial size artifacts due to its two-dimensional (2D) nature, so GWAS on BMD will pick up genetic variation in genes affecting growth plate chondrogenesis the same way as those affecting bone mass accrual.

#### *Organizing and maximizing rare HBM disease biological sample data*

Recent advances in genomic technologies have substantially shortened the diagnostic pathway for rare monogenic HBM disorders, but there is a large amount of data to be managed and analyzed with only a limited number of patients.<sup>(151)</sup> A way to circumvent this bioinformatic challenge is to establish a standardized, and easily accessible registry for HBM patients, clinicians, and basic/translational scientists.<sup>(152)</sup> Similar registries have successfully been set up for other rare bone disorders, such as osteogenesis imperfecta (ROI) (<https://oif.org/oiregistry/>), Ehlers-Danlos syndrome (RED) (<https://www.ehlers-danlos.com/eds-global-registry/>), hypophosphatasia (<https://hppregistry.com/>), and unifying registries such as the European Registry for rare bone and mineral conditions (<https://eur-bone.com/>). An

HBM registry could be a pivotal tool to support HBM research and patient management, because the primary aims are collection, analysis, and dissemination of information on a group of people defined by a rare but particular phenotype. To enable data pooling of patients suffering orphan diseases, an input of standardized data is strictly necessary. The use of Human Phenotype Ontology (HPO) terms for phenotypic descriptions (eg, data extracted from X-rays, bone biopsies) of (un)known HBM disorders, ORPHAcodes and OMIM numbering for referencing HBM disorders and HGVS nomenclature are good examples of standardized approaches to follow. Active inclusion of our classification of HBM genes according to their biological function (Table 1) could be incorporated. Defining a minimum common dataset based on our classification of HBM genes would aid collection of standardized data.

Because HBM cases are few, in-depth phenotyping is crucial. HBM patients are traditionally screened with X-ray-based methods, and phenotyping is based on radiographs and/or by DXA BMD measurements. Besides density measurements, more precise information regarding bone strength, microarchitecture, and fracture risk can be collected by performing high-resolution peripheral quantitative computed tomography (HR-pQCT) in parallel. However, its value in routine clinical care of HBM patients must be further explored.<sup>(153)</sup> Phenotypic data derived from serum analysis of bone turnover markers and a transiliac bone biopsy also provide highly valuable insights for HBM diagnostics such as activity and histology of bone cells, structural and dynamic bone properties, matrix composition, and bone mineral density distribution. However, taking a bone biopsy remains an invasive procedure. Alternatively, the use of patient-derived iPSCs in a clinical setting could be less invasive by differentiating iPSCs into specialized bone cell types using bone matrix scaffolds for laboratory testing (eg, omics, activity, morphology).<sup>(120,121)</sup>

Detailed phenotyping, state-of-the-art genetic screening strategies, and linking genotype–phenotype information to an affected mechanism can make a stark difference in future VUS interpretation for HBM phenotypes. Our classification of HBM genes can be a key tool here (Table 1). Because (sub)groups were labeled with GO accession numbers, this may provide a novel way of interpreting unknown HBM phenotypes or VUS in the clinic based on phenotypic/biological/molecular overlaps within this classification. Especially in multidisciplinary teams, this classification can provide a unified and unifying way to look at novel HBM phenotypes or genes, to ideally shorten the diagnostic timeframe.

#### *Artificial intelligence–based technologies to boost HBM diagnostics*

Artificial intelligence (AI) algorithms that deploy machine learning and deep neural networks are increasingly used to augment and automate HTS data analysis, eg, improved base calling<sup>(154)</sup> and variant annotation accuracy,<sup>(155)</sup> better detection and prediction of both coding<sup>(156–158)</sup> and non-coding pathogenic variants.<sup>(159,160)</sup> Deep neural networks, or deep learning, builds up from training datasets (eg, images, DNA/amino acid sequences) to perform enhanced predictions on novel unseen data, so that large amounts of data can be used to make objective classifications or predictions, uncovering novel hypothesis-free (unsupervised) insights that can guide the diagnostic and treatment options of a patient.

AI-based models have already shown promise in phenotype–genotype mapping, using for example electronic health records and facial images (ie, DeepGestalt, Face-2-Gene) for variant

prioritization<sup>(161,162)</sup> or by combining WGS data and automated phenotyping, through clinical natural language processing (CNLP) on electronic health records.<sup>(163)</sup> AI-based tools that combine HTS and phenotypic data (eg, HPO-terminology) are also already available to generate provisional clinical and molecular diagnoses, such as Moon (<https://www.diploid.com/moon>).<sup>(164)</sup> Creating AI-based initiatives, eg, on extraction of data from histological/X-ray images, may have potential for HBM phenotypic evaluations and genetic testing in the future.

AI also has the potential to aid in VUS interpretation, such as the recently developed deep neural network AlphaFold, that can predict 3D protein structures with atomic accuracy.<sup>(163,165)</sup> For the human proteome, Tunyasuvunakool and colleagues<sup>(165)</sup> expanded its structural coverage by applying AlphaFold at a scale covering almost all human proteins. These predictions are freely available to the community and anticipate that routine large-scale and high-accuracy structure prediction will become a valuable tool to address new questions in terms of VUS interpretation (AlphaFold Protein Structure Database, <https://alphafold.com/>).<sup>(165,166)</sup> Deep learning models have also been trained to further annotate amino acid sequence with protein function throughout the proteome, by using the protein family's database (Pfam; <https://www.ebi.ac.uk/interpro/>).<sup>(167)</sup> Advances in the coverage of Pfam also suggest that deep learning models will be a core component of future protein annotation tools and VUS interpretation. Finally, interpreting the effects of noncoding variation on gene expression in different cell types remains a major unsolved problem.<sup>(168)</sup> Deep learning models, such as Enformer, can predict gene expression and chromatin states from DNA sequences and may improve the future understanding of transcriptional regulation of HBM disorders (eg, enhancer–promoter interactions).<sup>(168)</sup>

## Future Perspectives


In this review, we collated the available knowledge on HBM, which requires a multifaceted effort. In light of this, we propose triangulation of data generated by basic research from multiple disciplines to improve clinical HBM diagnostics and discover new therapeutic targets for metabolic bone disorders. Our initiative to create a classification system based on biological function may become a valuable tool for researchers and clinicians. A recent screening of pathogenic variants in known HBM genes in an extended HBM cohort identified the genetic cause in only 3% of all cases.<sup>(5)</sup> A significant percentage of the remaining ones are assumed to have a polygenic explanation, but monogenic causes are definitely also missed. These could involve undetected noncoding or copy number variants as well as the involvement of currently unknown modifier genes. We therefore believe that a preferred use of reverse genetic strategies can accelerate novel gene discoveries in the future (Fig. 3). This will be essential to reveal novel HBM genes and their regulatory mechanisms belonging to a given HBM group. The list in Table 1 will undoubtedly continue growing, with generation of novel (sub)groups of the proposed classification.

Compared to other fields of study, the HBM field has not published many studies with omic assessments. Practical factors constitute standing bottlenecks, such as bone tissue being difficult to obtain, taking a long time to grow, and containing a variety of cell types, which all together limit a broader use of omics technologies. As each omic study captures a snapshot of a biological process in time and place, certain considerations should be

taken into account when interpreting results: (i) statistical analyses can be challenging as they capture thousands of measurements that can vary greatly between individuals; (ii) the bio-organization of bone tissue is complex and multilayered (ie, epigenetics, transcriptional and translational inhibition processes, protein dynamics, etc.) resulting in a single omic dataset not necessarily capturing the full biological landscape; and (iii) variation between model organisms, tissues, cell types, bone elements, and state of differentiation could impact the results. Key findings should therefore be replicated with independent experiments in preferably multiple systems that are relevant to HBM biology. Misra and colleagues<sup>(54)</sup> described an integrated multiomics approach to capture causal relationships between “functional potential” and actual “biological activity,” to visualize the actual disease state and provide new HBM candidate genes. This requires an interdisciplinary and multi-laboratory approach to share knowledge and expertise, especially in the case of rare disorders, to fully define the molecular landscape of HBM.

Similarly for the clinic, the preferred use of WGS for diagnostics of HBM cases will circumvent the inherent blind spot of WES data. Here, our HBM classification system (Table 1) will also aid in the generation of adequate hypotheses to reduce the diagnostic timeframe. Improved, in-depth phenotyping of HBM patients and setting up a HBM registry are essential as well. New candidate gene discovery can be sped up by triangulating VUS filtered WGS genetic findings with multiomics data sets relevant to a particular HBM group (Fig. 3). Currently, the use of patient iPSCs within the HBM field is still very limited due to cost and complexity of the applied methods, although there is great potential to use it in a clinical setting. Combining patient iPSC-derived 3D organoid models with other functional genomics tools may also enable a comprehensive translational angle, again allowing novel insights from patient to model system.

An improved diagnosis, classification, and understanding of HBM disorders can impact the treatment and prevention of severe symptoms in affected individuals, often occurring secondary to HBM. For example, affected individuals from HBM group 1A (“Regulation of ossification”—“Regulation of WNT signaling”) often suffer from hearing loss or severe headaches due to progressive cranial hyperostosis and nerve entrapment. Ideally, identification of a variant in a known or novel HBM gene from this particular HBM subgroup could then impact the follow-up of the affected individual in the clinic to prevent secondary symptoms and improve prognosis to a maximum extent. Deploying a translational pipeline approach that connects the bench with the clinic can also result in the development of targeted and personalized gene-driven or mutation-driven therapies, including reprogrammed iPSCs and BMSCs. The need for funding programs that facilitate formation of large consortia allowing for networking of multidisciplinary researchers (eg, COST Actions, European Reference Networks) and undertaking of basic and clinical research (eg, Horizon Europe grants, NIH and other governmental grants) is imperative to attain this goal. Moreover, the use of mRNA-based therapies could hugely impact HBM disorders, especially for those that are ultrarare. For example, disorders included in HBM group 8 (“Regulation of catalytic activity,” Table 1) can be targeted for enzyme replacement therapy (ERT), which has been used to treat rare and severe conditions such as hypophosphatasia (asfotase alfa; U.S. Food and Drug Administration [FDA] approved [September 2022]), mucopolysaccharidosis type VI (galsulfase; FDA-approved [September 2022]), and the ABCC6 deficiency (INZ-701; phase 1/2 clinical trial [September 2022]).<sup>(169–171)</sup> Future challenges remain



**Fig. 3.** Connecting the bench and clinic with a multidisciplinary reverse genetics pipeline. The reverse genetics pipeline starts with performing functional studies on known HBM genes or risk factors in model systems (panel I). Large-scale omic approaches allow mapping of disrupted regulatory networks relevant to a specific HBM group. The HBM group classification system allows us to potentially predict which mechanisms may be affected. concurrent phenotyping of genetically unsolved HBM cases may therefore link a phenotype with a pathway or biological process (panel II). By intersecting omic data-set from model systems of that HBM group and with genomic HBM patient data could provide (novel) candidate genes (panel III). HBM = high bone mass; VUS = variants of uncertain significance.

in the development of appropriate delivery methods, especially for notoriously difficult to target cell types, such as osteoblasts. We propose a paradigm shift toward a multidimensional approach based on reverse genetics because this could accelerate the identification of novel therapeutic targets and drugs for HBM disorders that may also benefit rare and common disorders of bone fragility.

## Acknowledgments

This publication is initiated upon work from the European Cooperation for Science and Technology (COST) Action GEMSTONE, supported by COST. COST is a funding agency for research and

innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation ([www.cost.eu](http://www.cost.eu)). We therefore thank current and former members of the COST GEMSTONE Working Group 3 (<https://cost-gemstone.eu/working-groups/wg3-monogenic-conditions-human-ko-models/>) for discussions and support during manuscript preparation. All figures in this manuscript were created with <https://biorender.com>. DB received funding from Versus Arthritis (Foundation Fellowship, grant # 22044); AM received funding from Fondazione Telethon (GGP20074), the American Society for Bone and Mineral Research (ASBMR Rising Star 2021); MMF is supported by the Malta Council for Science & Technology (GeOM REP-2020-011 and MetaBone REP-2021-012,

for and on behalf of the Foundation for Science and Technology, through the Research Excellence Programme); GMCD is funded by the Wellcome Trust Dynamic Cell doctoral training program (108907/Z/15/Z); NH is funded by the Medical Research Council (Clinical Research Training Fellowship MR/V00199X/1); F.R. is funded by LEGENDARE ERC-ADG 2020 101021500 grant; I.D. received funding (PID2020-117255RB-100); OM received funding from the Sigrid Jusélius Foundation, the Novo Nordisk Foundation and the Academy of Finland; WVH was supported by a Methusalem-OEC grant—“GENOMED” (Grant Number: FFB190208). The GEMSTONE initiative is funded by the COST action grant #CA18139.

## Author Contributions

**Dylan J.M. Bergen:** Conceptualization; funding acquisition; supervision; writing – original draft; writing – review and editing. **Antonio Maurizi:** Conceptualization; funding acquisition; supervision; writing – original draft; writing – review and editing. **Melissa M. Formosa:** Conceptualization; funding acquisition; visualization; writing – original draft; writing – review and editing. **Georgina L.K. McDonald:** Funding acquisition; visualization; writing – original draft; writing – review and editing. **Ahmed El-Gazzar:** Visualization; writing – review and editing. **Neelam Hassan:** Funding acquisition; writing – original draft. **Maria Luisa Brandi:** Writing – review and editing. **Jose Antonio Riancho:** Writing – review and editing. **FERNANDO RIVADENEIRA:** Funding acquisition; writing – review and editing. **Evangelia Ntzani:** Writing – review and editing. **Emma L Duncan:** Writing – original draft; writing – review and editing. **Celia L Gregson:** Writing – review and editing. **Douglas P. Kiel:** Writing – review and editing. **M. Carola Zillikens:** Writing – review and editing. **Luca Sangiorgi:** Writing – original draft; writing – review and editing. **Wolfgang Högl:** Conceptualization; writing – original draft; writing – review and editing. **Ivan Duran:** Funding acquisition; visualization; writing – original draft; writing – review and editing. **Outi Makitie:** Conceptualization; funding acquisition; writing – original draft; writing – review and editing. **Wim Van Hul:** Conceptualization; funding acquisition; writing – original draft; writing – review and editing. **Gretl Hendrickx:** Conceptualization; supervision; visualization; writing – original draft; writing – review and editing.

## Conflicts of Interest

AEG has received honoraria from Alexion, AstraZeneca Rare Disease. MLB has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB. MoLB received grants and/or was a speaker: Abiogen, Alexion, Amgen, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Eli Lilly, Enterabio, Gedeon Richter, Italfarmaco, Kyowa Kirin, Menarini, Monte Rosa, SPA, Takada, Theramex, UCB. MLB was a consultant for Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics, UCB. JAR has received research grants, travel grants or lecture fees from Merck, UCB, Amgen, Gedeon Richter, Lilly, Alexion, Takeda and Kyowa Kirin. OM has consulted for or received lecture fees from Kyowa Kirin, BridgeBio, Alexion, Sandoz, and Ultragenyx. ELD has received honoraria for research purposes from Kyowa Kirin and Pharmacosomos, and previously personally from Amgen. WVH received research grants from Roche and Johnson & Johnson and lecture fees or travel grants from Amgen, UCB, and Novartis. All other authors state that they have no conflicts of interest with respect to the submitted manuscript.

## Peer Review

The peer review history for this article is available at <https://publons.com/publon/10.1002/jbmr.4715>.

## Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

## References

- Hendrickx G, Boudin E, Van Hul W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. *Nat Rev Rheumatol*. 2015;11(8):462-474.
- Costantini A, Makitie RE, Hartmann MA, et al. Early-onset osteoporosis: rare monogenic forms elucidate the complexity of disease pathogenesis beyond type I collagen. *J Bone Miner Res*. 2022; 37(9):1623-1641.
- Foessel I, Bassett JHD, Bjornerem A, et al. Bone phenotyping approaches in human, mice and zebrafish—expert overview of the EU cost action GEMSTONE (“Genomics of MusculoSkeletal traits TranslatiOnal Network”). *Front Endocrinol (Lausanne)*. 2021;12: 720728.
- Formosa MM, Bergen DJM, Gregson CL, et al. A roadmap to gene discoveries and novel therapies in monogenic low and high bone mass disorders. *Front Endocrinol (Lausanne)*. 2021;12:709711.
- Gregson CL, Duncan EL. The genetic architecture of high bone mass. *Front Endocrinol (Lausanne)*. 2020;11:595653.
- Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). *Hum Mol Genet*. 2001;10(5):537-543.
- Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. *Am J Hum Genet*. 2001;68(3):577-589.
- Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. *J Med Genet*. 2002;39(2):91-97.
- Rauner M, Taipaleenmäki H, Tsoouri E, Winter EM. Osteoporosis treatment with anti-Sclerostin antibodies—mechanisms of action and clinical application. *J Clin Med*. 2021;10(4):787.
- Kaliya-Perumal AK, Carney TJ, Ingham PW. Fibrodysplasia ossificans progressiva: current concepts from bench to bedside. *Dis Model Mech*. 2020;13(9):dmm046441.
- Akesson LS, Savarirayan R. Fibrodysplasia ossificans progressiva. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. *GeneReviews*(R). Seattle (WA): University of Washington; 1993.
- McInerney-Leo AM, Duncan EL. Massively parallel sequencing for rare genetic disorders: potential and pitfalls. *Front Endocrinol (Lausanne)*. 2020;11:628946.
- Bean LJH, Funke B, Carlston CM, et al. Diagnostic gene sequencing panels: from design to report—a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2020;22(3):453-461.
- Hendrickx G, Borra VM, Steenackers E, et al. Conditional mouse models support the role of SLC39A14 (ZIP14) in hyperostosis cranialis interna and in bone homeostasis. *PLoS Genet*. 2018;14(4): e1007321.
- Gregson CL, Bergen DJM, Leo P, et al. A rare mutation in SMAD9 associated with high bone mass identifies the SMAD-dependent BMP signaling pathway as a potential anabolic target for osteoporosis. *J Bone Miner Res*. 2020;35(1):92-105.
- Whyte MP, McAlister WH, Zhang F, et al. New explanation for autosomal dominant high bone mass: mutation of low-density lipoprotein receptor-related protein 6. *Bone*. 2019;127:228-243.
- Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden testing of rare variants identified through exome sequencing



- via publicly available control data. *Am J Hum Genet.* 2018;103(4):522-534.
18. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581(7809):434-443.
  19. Sebastian A, Loots GG. Genetics of SOST/SOST in sclerosteosis and van Buchem disease animal models. *Metabolism.* 2018;80:38-47.
  20. Kim SJ, Bieganski T, Sohn YB, et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. *Hum Genet.* 2011;129(5):497-502.
  21. de Vernejoul MC. Sclerosing bone disorders. *Best Pract Res Clin Rheumatol.* 2008;22(1):71-83.
  22. Huybrechts Y, Mortier G, Boudin E, Van Hul W. WNT signaling and bone: lessons from skeletal dysplasias and disorders. *Front Endocrinol (Lausanne).* 2020;11:165.
  23. Costantini A, Kekäläinen P, Mäkitie RE, Mäkitie O. High bone mass due to novel LRP5 and AMER1 mutations. *Eur J Med Genet.* 2017;60(12):675-679.
  24. Peng H, Jenkins ZA, White R, et al. An activating variant in CTNBB1 is associated with a sclerosing bone dysplasia and adrenocortical neoplasia. *J Clin Endocrinol Metab.* 2020;105(3):dgaa034.
  25. White J, Mazzeu JF, Hoischen A, et al. DVL1 frameshift mutations clustering in the penultimate exon cause autosomal-dominant Robinow syndrome. *Am J Hum Genet.* 2015;96(4):612-622.
  26. Kiper POS, Saito H, Gori F, et al. Cortical-bone fragility—insights from sFRP4 deficiency in Pyle's disease. *N Engl J Med.* 2016;374(26):2553-2562.
  27. Kang H, Jha S, Ivovic A, et al. Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF- $\beta$ /SMAD pathway. *J Exp Med.* 2020;217(5):e20191499.
  28. Hellems J, Preobrazhenska O, Willaert A, et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. *Nat Genet.* 2004;36(11):1213-1218.
  29. Whyte MP, Griffith M, Trani L, et al. Melorheostosis: exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. *Bone.* 2017;101:145-155.
  30. De Ridder R, Boudin E, Zillikens MC, et al. A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis. *Bone.* 2020;137:115406.
  31. Lui JC, Raimann A, Hojo H, et al. A neomorphic variant in SP7 alters sequence specificity and causes a high-turnover bone disorder. *Nat Commun.* 2022;13(1):700.
  32. Price JA, Bowden DW, Wright JT, Pettenati MJ, Hart TC. Identification of a mutation in DLX3 associated with tricho-dento-osseous (TDO) syndrome. *Hum Mol Genet.* 1998;7(3):563-569.
  33. Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. *Nat Rev Endocrinol.* 2013;9(9):522-536.
  34. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. *Nat Genet.* 2007;39(8):960-962.
  35. Guerrini MM, Sobacchi C, Cassani B, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. *Am J Hum Genet.* 2008;83(1):64-76.
  36. Zonana J, Elder ME, Schneider LC, et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). *Am J Hum Genet.* 2000;67(6):1555-1562.
  37. Chalhoub N, Benachenhou N, Rajapurohitam V, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. *Nat Med.* 2003;9(4):399-406.
  38. Cleiren E, Benichou O, Van Hul E, et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the CICN7 chloride channel gene. *Hum Mol Genet.* 2001;10(25):2861-2867.
  39. Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. *Nat Genet.* 2000;25(3):343-346.
  40. Kornak U, Kasper D, Bosl MR, et al. Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. *Cell.* 2001;104(2):205-215.
  41. Venta PJ, Welty RJ, Johnson TM, Sly WS, Tashian RE. Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 his $\rightarrow$ Tyr): complete structure of the normal human CA II gene. *Am J Hum Genet.* 1991;49(5):1082-1090.
  42. Del Fattore A, Fornari R, Van Wesenbeeck L, et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. *J Bone Miner Res.* 2008;23(3):380-391.
  43. Van Wesenbeeck L, Odgren PR, Coxon FP, et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. *J Clin Invest.* 2007;117(4):919-930.
  44. Aker M, Rouvinski A, Hashavia S, et al. An SNX10 mutation causes malignant osteopetrosis of infancy. *J Med Genet.* 2012;49(4):221-226.
  45. Campeau PM, Lu JT, Sule G, et al. Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. *Hum Mol Genet.* 2012;21(22):4904-4909.
  46. Rolvien T, Koehne T, Kornak U, et al. A novel ANO5 mutation causing gnathodiaphyseal dysplasia with high bone turnover osteosclerosis. *J Bone Miner Res.* 2017;32(2):277-284.
  47. Xue JY, Grigelioniene G, Wang Z, et al. SLC4A2 deficiency causes a new type of Osteopetrosis. *J Bone Miner Res.* 2022;37(2):226-235.
  48. Shteyer E, Saada A, Shaag A, et al. Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene. *Am J Hum Genet.* 2009;84(3):412-417.
  49. Sohn M, Ivanova P, Brown HA, et al. Lenz-Majewski mutations in PTSS1 affect phosphatidylinositol 4-phosphate metabolism at ER-PM and ER-Golgi junctions. *Proc Natl Acad Sci U S A.* 2016;113(16):4314-4319.
  50. Dias C, Rupps R, Millar B, et al. Desmosterolosis: an illustration of diagnostic ambiguity of cholesterol synthesis disorders. *Orphanet J Rare Dis.* 2014;9:94.
  51. Wang Q, Li Y-h, Lin G-l, et al. Primary hypertrophic osteoarthropathy related gastrointestinal complication has distinctive clinical and pathological characteristics: two cases report and review of the literature. *Orphanet J Rare Dis.* 2019;14(1):297.
  52. Terhal PA, Vlaar JM, Middelkamp S, et al. Biallelic variants in POLR3GL cause endosteal hyperostosis and oligodontia. *Eur J Hum Genet.* 2020;28(1):31-39.
  53. Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. *Am J Med Genet A.* 2019;179(12):2393-2419.
  54. Misra BB, Langefeld CD, Olivier M, Cox LA. Integrated omics: tools, advances, and future approaches. *J Mol Endocrinol.* 2019;62(1):R21-R45.
  55. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. *Bioinform Biol Insights.* 2020;14:1177932219899051.
  56. Zhou Y, Gao Y, Xu C, Shen H, Tian Q, Deng H-W. A novel approach for correction of crosstalk effects in pathway analysis and its application in osteoporosis research. *Sci Rep.* 2018;8(1):668.
  57. Ilmer M, Karow M, Geissler C, Jochum M, Neth P. Human osteoblast-derived factors induce early osteogenic markers in human mesenchymal stem cells. *Tissue Eng Part A.* 2009;15(9):2397-2409.
  58. Gong Y, Yang J, Li X, et al. A systematic dissection of human primary osteoblasts in vivo at single-cell resolution. *Aging (Albany NY).* 2021;13(16):20629-20650.
  59. Yang X, Li J, Zhao L, et al. Targeting adipocytic discoidin domain receptor 2 impedes fat gain while increasing bone mass. *Cell Death Differ.* 2022;29(4):737-749.
  60. Sebastian A, Hum NR, Muruges DK, Hatsell S, Economides AN, Loots GG. Wnt co-receptors Lrp5 and Lrp6 differentially mediate Wnt3a signaling in osteoblasts. *PLoS One.* 2017;12(11):e0188264.

61. Aliprantis AO, Ueki Y, Sulyanto R, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. *J Clin Investig.* 2008;118(11):3775-3789.
62. Yoshioka H, Okita S, Nakano M, et al. Single-cell RNA-sequencing reveals the breadth of osteoblast heterogeneity. *JBMR Plus.* 2021; 5(6):e10496.
63. Zou W, Rohatgi N, Brestoff JR, et al. Ablation of fat cells in adult mice induces massive bone gain. *Cell Metab.* 2020;32(5):801-813.e6.
64. Droscha CJ, Diegel CR, Ethen NJ, et al. Osteoblast-specific deletion of *Hrpt2/Cdc73* results in high bone mass and increased bone turnover. *Bone.* 2017;98:68-78.
65. Frey JL, Li Z, Ellis JM, et al. Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. *Mol Cell Biol.* 2015;35(11):1979-1991.
66. Shi C, Uda Y, Dedic C, et al. Carbonic anhydrase III protects osteocytes from oxidative stress. *FASEB J.* 2018;32(1):440-452.
67. Kondoh S, Inoue K, Igarashi K, et al. Estrogen receptor  $\alpha$  in osteocytes regulates trabecular bone formation in female mice. *Bone.* 2014;60:68-77.
68. Liu S, Tang W, Fang J, et al. Novel regulators of *Fgf23* expression and mineralization in Hyp bone. *Mol Endocrinol.* 2009;23(9):1505-1518.
69. Quarto N, Shailendra S, Meyer NP, Menon S, Renda A, Longaker MT. *Twist1*-haploinsufficiency selectively enhances the osteoskeletal capacity of mesoderm-derived parietal bone through downregulation of *Fgf23*. *Front Physiol.* 2018;9:1426.
70. Mo C, Guo J, Qin J, et al. Single-cell transcriptomics of *LepR*-positive skeletal cells reveals heterogeneous stress-dependent stem and progenitor pools. *EMBO J.* 2022;41(4):e108415.
71. Sivaraj KK, Majev PG, Jeong HW, et al. Mesenchymal stromal cell-derived septoclasts resorb cartilage during developmental ossification and fracture healing. *Nat Commun.* 2022;13(1):571.
72. Wu J, Wang R, Kan X, et al. A sonic hedgehog-Gli-Bmi1 signaling pathway plays a critical role in p27 deficiency induced bone anabolism. *Int J Biol Sci.* 2022;18(3):956-969.
73. Norwood I, Szondi D, Ciocca M, et al. Transcriptomic and bioinformatic analysis of *Clcn7*-dependent autosomal dominant osteopetrosis type 2. Preclinical and clinical implications. *Bone.* 2021;144: 115828.
74. Youtlen SE, Kemp JP, Logan JG, et al. Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease. *Nat Commun.* 2021; 12(1):2444.
75. Wang N, Niger C, Li N, Richards GO, Skerry TM. Cross-species RNA-Seq study comparing transcriptomes of enriched osteocyte populations in the tibia and skull. *Front Endocrinol (Lausanne).* 2020;11: 581002.
76. Ohsugi Y, Katagiri S, Hirota T, et al. Laser irradiation decreases sclerostin expression in bone and osteogenic cells. *FASEB J.* 2020;34(9): 12877-12893.
77. Schebesta M, Lien C-L, Engel FB, Keating MT. Transcriptional profiling of caudal fin regeneration in zebrafish. *Sci World J.* 2006;6:38-54.
78. Liu R, Imangali N, Ethiraj LP, Carney TJ, Winkler C. Transcriptome profiling of osteoblasts in a Medaka (*Oryzias latipes*) osteoporosis model identifies *Mmp13b* as crucial for osteoclast activation. *Front Cell Dev Biol.* 2022;10:775512.
79. Tatarakis D, Cang Z, Wu X, et al. Single-cell transcriptomic analysis of zebrafish cranial neural crest reveals spatiotemporal regulation of lineage decisions during development. *Cell Rep.* 2021;37(12): 110140.
80. Zhang J-G, Tan L-J, Xu C, et al. Integrative analysis of transcriptomic and epigenomic data to reveal regulation patterns for BMD variation. *PLoS One.* 2015;10(9):e0138524.
81. Li C, Shangguan Y, Zhu P, et al. Multiomics landscape of the autosomal dominant osteopetrosis type II disease-specific induced pluripotent stem cells. *Hereditas.* 2021;158(1):40.
82. Nilsson KH, Henning P, El Shahawy M, et al. *RSPO3* is important for trabecular bone and fracture risk in mice and humans. *Nat Commun.* 2021;12(1):4923.
83. Kaya S, Schurman CA, Dole NS, Evans DS, Alliston T. Prioritization of genes relevant to bone fragility through the unbiased integration of aging mouse bone Transcriptomics and human GWAS analyses. *J Bone Miner Res.* 2022;37(4):804-817.
84. Bergen DJM, Tong Q, Shukla A, et al. Regenerating zebrafish scales express a subset of evolutionary conserved genes involved in human skeletal disease. *BMC Biol.* 2022;20(1):21.
85. Lee HJ, Hou Y, Chen Y, et al. Regenerating zebrafish fin epigenome is characterized by stable lineage-specific DNA methylation and dynamic chromatin accessibility. *Genome Biol.* 2020;21(1):52.
86. Fabian P, Tseng K-C, Thiruppathy M, et al. Lifelong single-cell profiling of cranial neural crest diversification in zebrafish. *Nat Commun.* 2022;13(1):13.
87. Rabinowitz JS, Robitaille AM, Wang Y, et al. Transcriptomic, proteomic, and metabolomic landscape of positional memory in the caudal fin of zebrafish. *Proc Natl Acad Sci U S A.* 2017;114(5):E717-E726.
88. Schmidt JR, Vogel S, Moeller S, et al. Sulfated hyaluronic acid and dexamethasone possess a synergistic potential in the differentiation of osteoblasts from human bone marrow stromal cells. *J Cell Biochem.* 2019;120(5):8706-8722.
89. Schmidt JR, Geurtzen K, von Bergen M, Schubert K, Knopf F. Glucocorticoid treatment leads to aberrant ion and macromolecular transport in regenerating zebrafish fins. *Front Endocrinol (Lausanne).* 2019;10:674.
90. Kessels MY, Huitema LFA, Boeren S, et al. Proteomics analysis of the zebrafish skeletal extracellular matrix. *PLoS One.* 2014;9(3):e90568.
91. Singh SK, Meena Lakshmi MG, Saxena S, Swamy CVB, Idris MM. Proteome profile of zebrafish caudal fin based on one-dimensional gel electrophoresis LCMS/MS and two-dimensional gel electrophoresis MALDI MS/MS analysis. *J Sep Sci.* 2011;34(2):225-232.
92. Saxena S, Singh SK, Lakshmi MG, et al. Proteomic analysis of zebrafish caudal fin regeneration. *Mol Cell Proteomics.* 2012;11(6): M111.014118.
93. Mesner LD, Calabrese GM, Al-Barghouthi B, et al. Mouse genome-wide association and systems genetics identifies *Lhfp* as a regulator of bone mass. *PLoS Genet.* 2019;15(5):e1008123.
94. Hartley A, Paternoster L, Evans DM, et al. Metabolomics analysis in adults with high bone mass identifies a relationship between bone resorption and circulating citrate which replicates in the general population. *Clin Endocrinol (Oxf).* 2020;92(1):29-37.
95. Han X, Wang R, Zhou Y, et al. Mapping the mouse cell atlas by microwell-Seq. *Cell.* 2018;172(5):1091-1107.e17.
96. Nagendra AH, Najar MA, Bose B, Shenoy PS. High concentration of sodium fluoride in drinking water induce hypertrophy versus atrophy in mouse skeletal muscle via modulation of sarcomeric proteins. *J Hazard Mater.* 2022;432:128654.
97. Mari-Beffa M, Mesa-Román AB, Duran I. Zebrafish models for human skeletal disorders. *Front Genet.* 2021;12:675331.
98. Carnovali M, Banfi G, Mariotti M. Zebrafish models of human skeletal disorders: embryo and adult swimming together. *Biomed Res Int.* 2019;2019:1253710.
99. Brommage R, Ohlsson C. High fidelity of mouse models mimicking human genetic skeletal disorders. *Front Endocrinol (Lausanne).* 2019;10:934.
100. Kogawa M, Wijenayaka AR, Ormsby RT, et al. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. *J Bone Miner Res.* 2013;28(12):2436-2448.
101. Spatz JM, Wein MN, Gooi JH, et al. The Wnt inhibitor Sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. *J Biol Chem.* 2015;290(27):16744-16758.
102. Tan SD, de Vries TJ, Kuijpers-Jagtman AM, Semeins CM, Everts V, Klein-Nulend J. Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption. *Bone.* 2007;41(5):745-751.
103. Lu XL, Huo B, Chiang V, Guo XE. Osteocytic network is more responsive in calcium signaling than osteoblastic network under fluid flow. *J Bone Miner Res.* 2012;27(3):563-574.
104. Riquelme MA, Burra S, Kar R, Lampe PD, Jiang JX. Mitogen-activated protein kinase (MAPK) activated by prostaglandin E2 phosphorylates Connexin 43 and closes osteocytic hemichannels in response

- to continuous flow shear stress. *J Biol Chem.* 2015;290(47):28321-28328.
105. Xu LH, Shao H, Ma YV, You L. OCY454 osteocytes as an in vitro cell model for bone remodeling under mechanical loading. *J Orthop Res.* 2019;37(8):1681-1689.
  106. Rauner M, Foessel I, Formosa MM, et al. Perspective of the GEMSTONE consortium on current and future approaches to functional validation for skeletal genetic disease using cellular, molecular and animal-modeling techniques. *Front Endocrinol (Lausanne).* 2021;12:731217.
  107. Ansari S, Ito K, Hofmann S. Cell sources for human in vitro bone models. *Curr Osteoporos Rep.* 2021;19(1):88-100.
  108. Vermeulen S, Tahmasebi Birgani Z, Habibovic P. Biomaterial-induced pathway modulation for bone regeneration. *Biomaterials.* 2022;283:121431.
  109. Moriishi T, Komori T. Osteocytes: their lacunocanalicular structure and mechanoresponses. *Int J Mol Sci.* 2022;23(8):4373.
  110. Gerondakis S, Grumont R, Gugasyan R, et al. Unravelling the complexities of the NF- $\kappa$ B signalling pathway using mouse knockout and transgenic models. *Oncogene.* 2006;25(51):6781-6799.
  111. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/ $\beta$ -catenin activation promotes prostate tumor progression in a mouse model. *Oncogene.* 2011;30(16):1868-1879.
  112. Li M, Wan P, Wang W, Yang K, Zhang Y, Han Y. Regulation of osteogenesis and osteoclastogenesis by zoledronic acid loaded on biodegradable magnesium-strontium alloy. *Sci Rep.* 2019;9(1):933.
  113. Borciani G, Montalbano G, Baldini N, Cerqueni G, Vitale-Brovarone C, Ciapetti G. Co-culture systems of osteoblasts and osteoclasts: simulating in vitro bone remodeling in regenerative approaches. *Acta Biomater.* 2020;108:22-45.
  114. Akiva A, Melke J, Ansari S, et al. An organoid for woven bone. *Adv Funct Mater.* 2021;31(17):2010524.
  115. Park Y, Cheong E, Kwak J-G, Carpenter R, Shim J-H, Lee J. Trabecular bone organoid model for studying the regulation of localized bone remodeling. *Sci Adv.* 2021;7(4):eabd6495.
  116. Menale C, Campodoni E, Palagano E, et al. Mesenchymal stromal cell-seeded biomimetic scaffolds as a factory of soluble RANKL in Rankl-deficient Osteopetrosis. *Stem Cells Transl Med.* 2019;8(1):22-34.
  117. Cappariello A, Paone R, Maurizi A, et al. Biotechnological approach for systemic delivery of membrane receptor activator of NF- $\kappa$ B ligand (RANKL) active domain into the circulation. *Biomaterials.* 2015;46:58-69.
  118. Becerra J, Andrades JA, Ertl DC, Sorgente N, Nimni ME. Demineralized bone matrix mediates differentiation of bone marrow stromal cells in vitro: effect of age of cell donor. *J Bone Miner Res.* 1996;11(11):1703-1714.
  119. Hofmann S, Hagenmüller H, Koch AM, et al. Control of in vitro tissue-engineered bone-like structures using human mesenchymal stem cells and porous silk scaffolds. *Biomaterials.* 2007;28(6):1152-1162.
  120. Barruet E, Hsiao EC. Using human induced pluripotent stem cells to model skeletal diseases. *Methods Mol Biol.* 2016;1353:101-118.
  121. De Kinderen P, Meester J, Loeyts B, et al. Differentiation of induced pluripotent stem cells into chondrocytes: methods and applications for disease modeling and drug discovery. *J Bone Miner Res.* 2022;37(3):397-410.
  122. Li Y, Jia Z, Zhang S, He X. Progress in gene-editing technology of zebrafish. *Biomolecules.* 2021;11(9):1300.
  123. Mackay EW, Apschner A, Schulte-Merker S. A bone to pick with zebrafish. *Bonekey Rep.* 2013;2:445.
  124. Suniaga S, Rolvien T, Vom Scheidt A, et al. Increased mechanical loading through controlled swimming exercise induces bone formation and mineralization in adult zebrafish. *Sci Rep.* 2018;8(1):3646.
  125. Khajuria DK, Karasik D. Novel model of restricted mobility induced osteopenia in zebrafish. *J Fish Biol.* 2021;98(4):1031-1038.
  126. Bergen DJM, Kague E, Hammond CL. Zebrafish as an emerging model for osteoporosis: a primary testing platform for screening new osteo-active compounds. *Front Endocrinol (Lausanne).* 2019;10:6.
  127. Dietrich K, Fiedler IA, Kurzyukova A, et al. Skeletal biology and disease modeling in zebrafish. *J Bone Miner Res.* 2021;36(3):436-458.
  128. To TT, Witten PE, Renn J, Bhattacharya D, Huysseune A, Winkler C. Rankl-induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model. *Development.* 2012;139(1):141-150.
  129. Hur M, Gistelink CA, Huber P, et al. MicroCT-based phenomics in the zebrafish skeleton reveals virtues of deep phenotyping in a distributed organ system. *Elife.* 2017;6:e26014.
  130. Apschner A, Huitema LF, Ponsioen B, Peterson-Maduro J, Schulte-Merker S. Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE). *Dis Model Mech.* 2014;7(7):811-822.
  131. Spoorendonk KM, Peterson-Maduro J, Renn J, et al. Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in the axial skeleton. *Development.* 2008;135(22):3765-3774.
  132. Charles JF, Sury M, Tsang K, et al. Utility of quantitative micro-computed tomographic analysis in zebrafish to define gene function during skeletogenesis. *Bone.* 2017;101:162-171.
  133. Oosterhof N, Chang JJ, Karimiani EG, et al. Homozygous mutations in CSF1R cause a pediatric-onset leukoencephalopathy and can result in congenital absence of microglia. *Am J Hum Genet.* 2019;104(5):936-947.
  134. Seda M, Peskett E, Demetriou C, et al. Analysis of transgenic zebrafish expressing the Lenz-Majewski syndrome gene PTDS1 in skeletal cell lineages. *F1000Res.* 2019;8:273.
  135. Szabo A, Mayor R. Mechanisms of neural crest migration. *Annu Rev Genet.* 2018;52:43-63.
  136. Cerrizuela S, Vega-Lopez GA, Méndez-Maldonado K, Velasco I, Aybar MJ. The crucial role of model systems in understanding the complexity of cell signaling in human neurocristopathies. *WIREs Mech Dis.* 2022;14(1):e1537.
  137. Mayor R. Cell fate decisions during development. *Science.* 2019;364(6444):937-938.
  138. Vega-Lopez GA, Cerrizuela S, Tribulo C, Aybar MJ. Neurocristopathies: new insights 150 years after the neural crest discovery. *Dev Biol.* 2018;444:5110-5143.
  139. Duverger O, Isaac J, Zah A, et al. In vivo impact of Dlx3 conditional inactivation in neural crest-derived craniofacial bones. *J Cell Physiol.* 2013;228(3):654-664.
  140. Tsukamoto S, Mizuta T, Fujimoto M, et al. Smad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling. *Sci Rep.* 2014;4:7596.
  141. McDonald GLK, Wang M, Hammond CL, Bergen DJM. Pharmacological manipulation of early zebrafish skeletal development shows an important role for Smad9 in control of skeletal progenitor populations. *Biomolecules.* 2021;11(2):277.
  142. Topczewska JM, Shoela RA, Tomaszewski JP, Mirmira RB, Gosain AK. The morphogenesis of cranial sutures in zebrafish. *PLoS One.* 2016;11(11):e0165775.
  143. Kague E, Roy P, Asselin G, et al. Osterix/Sp7 limits cranial bone initiation sites and is required for formation of sutures. *Dev Biol.* 2016;413(2):160-172.
  144. Ho SS, Urban AE, Mills RE. Structural variation in the sequencing era. *Nat Rev Genet.* 2020;21(3):171-189.
  145. Muurinen M, Taylan F, Tournis S, et al. Mosaic deletions of known genes explain skeletal dysplasias with high and low bone mass. *JBMR Plus.* 2022;6(8):e10660.
  146. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-424.
  147. Morris JA, Kemp JP, Youtlen SE, et al. An atlas of genetic influences on osteoporosis in humans and mice. *Nat Genet.* 2019;51(2):258-266.

148. Zhu X, Bai W, Zheng H. Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications. *Bone Res.* 2021;9(1):23.
149. Fahed AC, Wang M, Homburger JR, et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. *Nat Commun.* 2020;11(1):3635.
150. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet.* 2018;50(9):1219-1224.
151. Decherchi S, Pedrini E, Mordenti M, Cavalli A, Sangiorgi L. Opportunities and challenges for machine learning in rare diseases. *Front Med (Lausanne).* 2021;8:747612.
152. Javaid MK, Mordenti M, Boarini M, et al. Patients' priorities and expectations on an EU registry for rare bone and mineral conditions. *Orphanet J Rare Dis.* 2021;16(1):463.
153. van den Bergh JP, Szulc P, Cheung AM, Bouxsein M, Engelke K, Chapurlat R. The clinical application of high-resolution peripheral computed tomography (HR-pQCT) in adults: state of the art and future directions. *Osteoporos Int.* 2021;32(8):1465-1485.
154. Boža V, Brejová B, Vinař T. DeepNano: deep recurrent neural networks for base calling in MinION nanopore reads. *PLoS One.* 2017;12(6):e0178751.
155. Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. *Bioinformatics.* 2015;31(5):761-763.
156. Sundaram L, Gao H, Padigepati SR, et al. Predicting the clinical impact of human mutation with deep neural networks. *Nat Genet.* 2018;50(8):1161-1170.
157. Qi H, Zhang H, Zhao Y, et al. MVP predicts the pathogenicity of missense variants by deep learning. *Nat Commun.* 2021;12(1):510.
158. De La Vega FM, Chowdhury S, Moore B, et al. Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases. *Genome Med.* 2021;13(1):153.
159. Xiong HY, Alipanahi B, Lee LJ, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. *Science.* 2015;347(6218):1254806.
160. Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based sequence model. *Nat Methods.* 2015;12(10):931-934.
161. Liang H, Tsui BY, Ni H, et al. Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence. *Nat Med.* 2019;25(3):433-438.
162. Gurovich Y, Hanani Y, Bar O, et al. Identifying facial phenotypes of genetic disorders using deep learning. *Nat Med.* 2019;25(1):60-64.
163. Clark MM, Hildreth A, Batalov S, et al. Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation. *Sci Transl Med.* 2019;11(489):eaat6177.
164. O'Brien TD, Campbell NE, Potter AB, Letaw JH, Kulkarni A, Richards CS. Artificial intelligence (AI)-assisted exome reanalysis greatly aids in the identification of new positive cases and reduces analysis time in a clinical diagnostic laboratory. *Genet Med.* 2022;24(1):192-200.
165. Tunyasuvunakool K, Adler J, Wu Z, et al. Highly accurate protein structure prediction for the human proteome. *Nature.* 2021;596(7873):590-596.
166. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature.* 2021;596(7873):583-589.
167. Bileschi ML, Belanger D, Bryant DH, et al. Using deep learning to annotate the protein universe. *Nat Biotechnol.* 2022;40(6):932-937.
168. Avsec Ž, Agarwal V, Visentin D, et al. Effective gene expression prediction from sequence by integrating long-range interactions. *Nat Methods.* 2021;18(10):1196-1203.
169. Hofmann C, Seefried L, Jakob F. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. *Drugs Today (Barc).* 2016;52(5):271-285.
170. Jacobs IJ, Cheng Z, Ralph D, et al. INZ-701, a recombinant ENPP1 enzyme, prevents ectopic calcification in an *Abcc6*<sup>-/-</sup> mouse model of pseudoxanthoma elasticum. *Exp Dermatol.* 2022;31(7):1095-1101.
171. Horovitz DDG, Magalhães TSPC, Acosta A, et al. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. *Mol Genet Metab.* 2013;109(1):62-69.